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 Nitro-fatty acids (NO2-FA) are endogenous mediators generated by reactions of nitrogen 
dioxide with unsaturated fatty acids. They are electrophilic and signal by reversibly reacting with 
nucleophilic cysteine and histidine residues on proteins, thus altering protein function. NO2-FA 
mediate cardioprotection in in vivo models of ischemia-reperfusion (IR) through not fully 
defined mechanisms. Mitochondria play a central role in both IR injury and redox signaling, with 
respiratory inhibition a common pathway in cardioprotective signaling. It was hypothesized that 
NO2-FA induce tissue-protective metabolic shifts through mitochondrial interactions. 
Respirometry in isolated mitochondria demonstrated that complex II-linked, but not 
complex I-linked, respiration was inhibited by nitro-oleic acid (OANO2). Activity assays showed 
that inhibition of complex II was pH-dependent and reversible by the low molecular weight thiol 
β-mercaptoethanol (BME). Modification of the Fp subunit of complex II was confirmed 
following electrophoresis of mitochondrial proteins from OANO2-treated lysates: addition of 
BME displaced protein-bound OANO2 and led to the formation of BME-OANO2 adducts as 
measured by liquid chromatography/mass spectrometry (LC/MS). Extracellular flux analysis, 
where O2 consumption and media acidification are measured as surrogates for respiratory and 
glycolytic activity, was employed to determine the effects of OANO2 on bioenergetics in 
cardiomyoblasts. Pre-incubation with OANO2 inhibited basal and maximal respiration, while 
acute OANO2 injection inhibited respiration and promoted glycolysis, a tissue-protective shift in 
IR. Protection against IR injury to the heart was observed in a Langendorff-perfused heart model 
as improved cardiac output recovery during reperfusion in the presence OANO2. 
Additional studies monitored metabolism of OANO2 in cardiac tissue and cells. NO2-FA 
are metabolized by prostaglandin reductase-1 (PGR1) and β-oxidation to yield non-electrophilic 
nitroalkanes and shorter chain nitroalkenes, respectively. PGR1 is inhibited by indomethacin and 
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β-oxidation by etomoxir, so these compounds were used to inhibit OANO2 metabolism. 
Indomethacin treatment attenuated OANO2 reduction and enhanced protein adduction by 
OANO2 and its electrophilic metabolites, while etomoxir favored the formation of non-
electrophilic nitroalkanes and reduced β-oxidation products. Indomethacin also significantly 
enhanced OANO2 signaling in cardiomyoblasts, elevating heme oxygenase-1 expression 
compared to OANO2 alone. This work identifies mitochondrial actions of NO2-FA relevant to 
cardioprotection, and illuminates NO2-FA metabolic pathways relevant to signaling in the 
myocardium. 
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1.0       INTRODUCTION 
Reactive species derived from oxygen and nitric oxide are produced during inflammation and 
promote oxidation and nitration of biomolecules, including unsaturated fatty acids. Among the 
products of these reactions are α,β-unsaturated carbonyl and nitro derivatives of fatty acids, 
electrophilic species whose reactivity with nucleophilic amino acids provides a means of post-
translational protein modification and signaling. These electrophilic fatty acids activate cytosolic 
and nuclear stress-response pathways (through Nrf2/Keap1 and PPARγ, for example). There is 
also growing evidence that mitochondria generate electrophilic species. This appreciation, when 
combined with the role of mitochondrial dysfunction in conditions where exogenously delivered 
electrophiles exhibit therapeutic benefit, suggests that mitochondrial electrophile targets are 
also important in the resolution and prevention of inflammatory injury. Cardioprotective signaling 
pathways in particular appear to converge on mitochondria, with nitro-fatty acids recently shown 
to protect against cardiac ischemia/reperfusion injury in a murine model. While numerous 
mitochondrial proteins are subject to modification by electrophiles, defining the targets most 
relevant to cytoprotection during inflammatory stress remains a clinically-relevant goal. 
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1.1 CARDIAC REPERFUSION INJURY 
Cardiovascular disease has been the leading cause of death in the United States every year 
since 1919, and myocardial ischemia in particular imposes a severe morbidity and mortality 
burden. 16.8 million Americans are estimated to have coronary heart disease, and each year 
over one million experience a new or recurrent coronary attack (1). Timely restoration of arterial 
patency is required for tissue preservation following acute myocardial infarction, and 
thrombolysis and percutaneous angioplasty have emerged as the therapeutic gold standards. 
However, the benefit of these approaches is limited by reperfusion injury, in which additional 
tissue damage accompanies the return of oxygenated blood to the ischemic heart. No clinical 
strategies for abrogating reperfusion injury currently exist, though there is ample interest: agents 
currently under study include calcium channel blockers, free radical scavengers, and nitric oxide 
donors (2). The recent observation that nitrated fatty acids, endogenous electrophilic species 
produced during inflammation, are cardioprotective in murine ischemia-reperfusion suggests 
that these compounds and their cellular targets may open new clinical avenues toward the 
prevention of reperfusion injury (3). 
1.2 REACTIVE GASES (O2, .NO), CELL SIGNALING AND INFLAMMATION 
When first characterized as a signaling molecule, the gaseous free radical nitric oxide (.NO) 
exhibited classical high-affinity ligand-receptor binding behavior with its specific receptor, the 
heme iron of soluble guanylate cyclase (sGC). Observations over the ensuing 20 years have 
augmented this view, revealing an expansive biochemical and physiological role for .NO in 
mammalian biology, with an ever-growing cast of molecular, cellular, and tissue targets.  
Chemically, .NO reacts with molecular oxygen (O2) and its derivatives (ROS) to generate 
a range of oxidation products (NOx) whose downstream reactivities greatly increase the breadth 
of what is termed “.NO signaling”. These reactive nitrogen species (RNS) differentially induce 
biomolecule oxidation, nitration (addition of NO2), and nitrosation (addition of NO), each of which 
has implications in cell signaling (4). One well-characterized RNS-forming reaction is that of .NO 
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with superoxide (O2
.-), which occurs at nearly diffusion-limited rates to produce peroxynitrite 
(ONOO-) (5). ONOO- is itself strongly oxidizing, and when protonated undergoes homolytic 
scission to produce hydroxyl radical (.OH) and nitrogen dioxide (.NO2), the latter a nitrating 
agent and the former the most potent biological oxidant (5). Moreover, ONOO- reacts avidly with 
CO2 to produce nitrosoperoxycarbonate (ONOOCO2-), a reaction of particular importance in 
acidic milieus which tips the balance in successive reactions toward nitration versus oxidation, 
and leads to the formation of a carbonate radical (HCO3
.) (6). Through its own activity and that 
of its byproducts, ONOO- engages in lipid and protein oxidation and nitration, enabling signal 
transduction and changes in cellular function (7). Radical reactions of .NO with molecular 
oxygen lead to an additional set of RNS with distinct properties. The reaction of .NO with one of 
the unpaired electrons of O2 forms 
.NO2, which may react further with 
.NO to yield N2O3 or 
N2O4—nitrosating and nitrating compounds, respectively (8). Ultimately, this array of reactions 
provides the palette from which .NO draws its myriad cGMP-independent in vivo effects (Figure 
1). 
Though many RNS facilitate pro-oxidant reactions, .NO predominantly mediates 
protective effects during inflammation (9). The selective modification of biomolecules by RNS to 
engage signaling pathways provides an appealing explanation for the inflammation-resolving 
effects of .NO. In particular, RNS (and ROS) interact with unsaturated fatty acids to form 
electrophilic lipid derivatives, a class of molecules gaining recognition for their anti-inflammatory 
effects. 
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Figure 1. Redox reactions of nitric oxide in inflammation and formation of nitrogen 
dioxide. The nitrating species nitrogen dioxide is generated by a variety of reactions in the 
inflammatory milieu. Following the rapid reaction of nitric oxide and superoxide, peroxynitrite 
(ONOO-) may react with carbon dioxide or be protonated, and in each case will decompose to 
form .NO2 along with another radical species. Oxidation of nitric oxide to nitrite can be followed 
by .NO2 formation as well in acidic compartments through the decomposition of N2O3. Finally, 
nitric oxide reaction with O2 can yield .NO2 directly. 
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1.3 CHARACTERISTICS AND REDOX-DEPENDENT GENERATION OF 
ELECTROPHILES 
An electrophile is a compound which forms a bond with a nucleophile by accepting an electron 
pair. This reaction occurs at an electron-poor region of the molecule whose presence can 
typically be attributed to a nearby electron-withdrawing substituent, most commonly a carbonyl 
(C=O). Electrophiles may be produced endogenously, obtained from the diet, or arise during 
metabolism of xenobiotics. Here we concern ourselves with endogenous electrophiles 
generated as by-products of lipid oxidation. 
Olefins conjugated to electron-withdrawing groups constitute a major portion of 
endogenously-produced electrophiles. Such compounds are products of cellular redox 
reactions, and while important in inflammation, are also produced in a tightly regulated fashion 
during normal metabolism. In the latter case production is predominantly enzymatic, while free 
radical-based non-enzymatic pathways become significant under oxidizing conditions. Notably, 
polyunsaturated fatty acids (PUFA) are highly susceptible to oxidation and readily undergo 
peroxidation by enzymatic or free radical chain reaction mechanisms, yielding numerous 
electrophilic species (10). 
Non-enzymatic peroxidation of unsaturated fatty acids is initiated by hydrogen 
abstraction from a methylene carbon along the lipid backbone, leaving an unpaired electron. 
Under aerobic conditions, this newly formed radical (L.) reacts rapidly with oxygen to form a lipid 
peroxyl radical (LOO.), which can be reduced to a hydroperoxide (LOOH), propagate the chain 
reaction by abstracting a proton from an adjacent PUFA or form an endoperoxide via cyclization 
(11). L. and LOO. may also react with other radical species such as .NO or .NO2 (12). 
Hydroperoxides and endoperoxides are unstable and decompose to form a variety of carbonyl-
containing compounds, some with electrophile functionality, while nitro-fatty acids formed by 
.NO2 addition acquire electrophilic character due to the strong electron-withdrawing activity of 
the nitro group (10,13). PUFA oxidation and peroxidation also occur enzymatically via 
cyclooxygenase (COX) and lipoxygenase (LOX) activities, and when followed by 
dehydrogenase metabolism can yield α,β-unsaturated carbonyl-containing electrophiles (10). 
Arachidonic acid (a ω-6 fatty acid) and longer-chain ω-3 fatty acids can be modified to produce 
electrophilic species by these enzymatic pathways. In brief, fatty acid-derived electrophiles can 
be considered in two groups: α,β-unsaturated carbonyls and nitro-fatty acids. 
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1.3.1 α,β-unsaturated carbonyls 
α,β-unsaturated carbonyls are a class of electrophiles whose ranks include the reactive 
aldehydes 4-hydroxynonenal (4-HNE), 4-oxononenal (4-ONE), and acrolein (2-propenal), as 
well as ω-3 and ω-6 fatty acid derivatives such as the cyclopentenone prostaglandins and oxo-
eicosatetraenoic acids (oxo-ETEs) (14). 4-HNE and 4-ONE are non-enzymatically derived, 
largely from decomposition of peroxidized linoleic acid. By this model, autoxidation of lineoleate 
forms 13-hydroperoxy-9,11-octadecaenoic acid (13-HPODE), which oxidatively decomposes to 
4-hydroperoxynonenal (HPNE). HPNE can be converted to either 4-HNE or 4-ONE by reduction 
or dehydrogenase activity, respectively (Figure 2) (15). Acrolein is produced during lipid 
peroxidation by poorly elucidated mechanisms, and is also formed during oxidation of 
carbohydrates and amino acids (16). 
ω-6-derived electrophiles are produced enzymatically via COX and LOX as products of 
the ω-6 fatty acid arachidonate. These include the A and J series of cyclopentenone 
prostaglandins, such as 15-deoxy-prostaglandin J2 (15d-PGJ2), along with the LOX-derived 5-, 
12-, and 15-oxo-ETEs (14). However, non-enzymatic pathways can yield similar or identical 
products to the above. Endoperoxides formed as intermediates during non-enzymatic 
peroxidation can undergo a series of internal rearrangements and reactions to form 
cyclopentenone structures containing α,β-unsaturated carbonyls (17). oxo-ETEs can also be 
generated through non-enzymatic lipid oxidation (18). ω-3 fatty acids are subject to many of the 
same oxidation pathways as ω-6 fatty acids, though their corresponding electrophilic species 
have distinct biological properties. It has been proposed that oxidation products of ω-3 fatty 
acids mediate their protective cardiovascular effects (19). 
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Figure 2. Non-enzymatic generation of electrophiles from linoleic acid. Following 
peroxidation of linoleic acid, 9(s)-hydroperoxyoctadecadienoic acid (HPODE) undergoes Hock 
fragmentation to form 3Z-nonenal. Peroxidation of this substrate yields the α,β-unsaturated 
carbonyl-containing electrophiles 4-hydroxynonenal and 4-oxononenal. 
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1.3.2 Nitro-fatty acids  
Nitro-fatty acids (NO2-FA) are electrophilic fatty acid derivatives that are a byproduct of 
lipid oxidation reactions involving reactive O2 and 
.NO-derived species. NO2-FA consist of an 
electron-withdrawing vinyl NO2 group present in an unsaturated fatty acid. 
.NO is lipophilic and 
tends to concentrate (roughly 20-fold) in lipid microenvironments, including the interiors of 
membranes and lipoproteins. Molecular O2 compartmentalizes similarly and consumes 
.NO, 
creating a molecular “lens” effect that accelerates .NO oxidation several hundred-fold and yields 
an array of oxidizing, nitrosating and nitrating species (20). Multiple RNS (.NO2, ONOO-, HNO2, 
NO2+) facilitate oxidation and nitration of PUFA. The nitrating compound 
.NO2 may form NO2-FA 
by hydrogen abstraction and reaction with L. radicals, while NO2+ mediates nitration by ionic 
addition mechanisms. ONOO- serves as a membrane-diffusible PUFA-nitrating agent. HNO2, 
which is the protonated form of nitrite (NO2-), has a pKa of 3.4, rendering it a possible player in 
NO2-FA formation in acidic tissues or organelle (21). Nitrite may also participate in nitration 
reactions indirectly, via its conversion to .NO and .NO2 by the nitrite reductase activity displayed 
by many heme-containing proteins. While all of these mechanisms may have a role in NO2-FA 
production in vivo, it remains unknown which predominate. It is clear, however, that NO2-FA 
production occurs in vivo in response to pathologic stress. A recent study demonstrated that 
mice that have undergone cardiac ischemia via a coronary artery ligation procedure generate 
increased levels of NO2-FA compared to sham controls (3). 
Thus, during oxidative stress and inflammation, ROS, RNS, and unsaturated fatty acids 
combine to generate various reactive electrophiles. Due to the signaling characteristics of 
electrophiles, the generation of these species has implications in the propagation and resolution 
of inflammatory disease. 
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1.4 SIGNALING ACTIONS OF ELECTROPHILES 
Like other reactive species since shown to be important in normal physiology, electrophiles 
were first recognized for their cytotoxicity. Indeed, electrophiles may have deleterious effects: 
alkylation of DNA by electrophilic compounds is a well-characterized phenomenon that 
promotes carcinogenesis, and large-scale or irreversible disruptions of protein function may lead 
to apoptotic or necrotic cell death. However, this view changed as various adaptive mechanisms 
for countering electrophilic stress were elucidated, and it is now appreciated that electrophiles at 
sub-toxic levels induce protective or adaptive responses to stress (22). Electrophilic lipids 
engage in cell signaling via Michael addition reactions with cellular nucleophiles (Figure 3). As 
these include cysteine thiols, the imidazole of histidine, and the ε-amino group of lysine, post-
translational modification is a major mode of electrophile signaling, leading to changes in protein 
trafficking, function and catalytic activity (23). Importantly, despite their similar chemical 
reactivities, different electrophiles may target distinct protein pools (24). Of particular importance 
are reactions with transcription factors, several of which are involved in coordinating cellular 
responses to electrophiles. 
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Figure 3. Thiol adduction by nitro-fatty acids. The electron-withdrawing nitro-group reduces 
electron density at the carbon indicated by an asterisk. This carbon is then subject to attack by a 
nucleophile (in this example, a cysteine thiolate). The Michael adduct thus formed represents a 
covalent, reversible modification. 
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1.4.1 Electrophile-activated signaling pathways 
A canonical example of genomic regulation common to most electrophiles is the Nrf2/Keap1 
(Nuclear erythroid 2-related factor 2/Kelch ECH associating protein) pathway. Under basal 
conditions, the transcription factor Nrf2 is held in the cytoplasm and tagged for proteasomal 
degradation through its regulator, Keap1, which possesses several reactive and evolutionarily 
conserved cysteine residues critical in maintaining its interaction with Nrf2. Covalent adduction 
of these cysteines releases Nrf2, which translocates to the nucleus and activates the cis-acting 
electrophile response element (ERE), which regulates the expression of phase-II genes 
involved in electrophile detoxification and restoration of redox balance, including glutathione S-
transferases (GSTs), heme oxygenase-1 (HO-1), thioredoxin, and components of the 
glutathione synthesis pathway (25). Another target of electrophiles, peroxisome proliferator-
activated receptor gamma (PPARγ) is a nuclear receptor involved in regulation of lipid 
metabolism and cell differentiation, and the target of the thiazoladinedione (TZD) class of anti-
hyperglycemic medications. In recent years various endogenous electrophiles have been 
promoted as endogenous PPARγ ligands, including the cyclopentenone prostaglandin 15d-PGJ2 
and NO2-FA. Unlike TZDs, these electrophiles bind the receptor covalently, and ultimately lead 
to a gene expression profile distinct from that of their synthetic counterparts (26). Electrophiles, 
notably 15d-PGJ2, 4-HNE, and NO2-FA, also signal through the heat-shock factor (HSF) family 
of transcription factors, leading to upregulation of chaperones (heat-shock proteins) involved in 
protein folding, trafficking, and turnover (27). In addition to the activation of cytoprotective 
signaling by these mechanisms, electrophiles downregulate the pro-inflammatory gene 
expression induced by nuclear factor κB (NF-κB), a multi-subunit transcription factor whose 
nuclear translocation is inhibited by its association with inhibitor of κB (IκB) under basal 
conditions. The NF-κB p50 and p65 subunits and IκB possess electrophile-reactive residues of 
functional significance, which when modified suppress NF-κB transcription of target genes by 
inhibiting translocation or impairing DNA binding (14). While these pathways illustrate the variety 
of cytoplasmic and nuclear signaling targets of electrophiles, mitochondrial transduction of 
electrophile signaling will be addressed in particular. 
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1.5 THE MITOCHONDRION AS A SOURCE AND TARGET OF ELECTROPHILES 
1.5.1 Electrophile generation by mitochondria 
As noted above, the generation of electrophiles frequently involves the interaction of oxidizing 
species and PUFA. Mitochondria are a prominent source of reactive oxygen and nitrogen 
species and possess an abundance of unsaturated fatty acids on the vast surface area of their 
inner membranes, thus representing a fertile environment for lipid peroxidation and electrophile 
production (28). In addition, cytochrome c, along with its involvement in electron transport, 
functions as a peroxidase when structurally destabilized by oxidation or upon interactions with 
anionic phospholipids. The result of this activity is primarily formation of hydroxy and 
hydroperoxy derivatives of cardiolipin, a phospholipid found exclusively in mitochondrial 
membranes. These oxidized species are critical factors in the induction of apoptosis through 
cytochrome c release (29). Oxidized fatty acids are preferentially hydrolyzed by mitochondrial 
phospholipase A2 (PLA2) activity, and may be modulated by ROS production—one 
mitochondrial PLA2 isoform is activated by superoxide (30). Combined, these activities may 
provide a mechanism for the generation of free electrophilic fatty acid derivatives by 
mitochondria.  
Mitochondria are also involved in the production of NO2-FA. For example, mitochondrial 
NO2-FA levels increase following ischemic preconditioning of ex vivo Langendorff-perfused 
mouse hearts, to an estimated concentration of several hundred nanomolar within the organelle 
(31). Additional evidence of mitochondrial NO2-FA production comes from recent studies using 
isolated rat liver mitochondria, which produce [15N] nitro-oleic and nitro-linoleic acid when 
supplied with only [15N] NO2-, as demonstrated by LC/MS analysis. NO2-FA production 
increases only slightly in the presence of substrate, but is abolished by addition of sodium 
cyanide. However, inhibition of complex I with rotenone has no effect on NO2-FA levels, 
suggesting that function of only downstream respiratory chain components is required (32). The 
mechanism of NO2-FA synthesis under these conditions remains undefined, and work to 
determine factors that modulate NO2-FA production from NO2- is ongoing.  
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1.5.2 Mitochondrial targets of electrophiles 
In light of these observations, mitochondria likely experience high local concentrations of 
electrophilic fatty acid derivatives, and electrophile effects within mitochondria should be 
relevant in normal and oxidatively perturbed physiology. Importantly, mitochondria are enriched 
in thiol-containing proteins that are subject to Michael addition reactions, and the relatively high 
matrix pH increases the amount of thiolate anion available for these reactions. One broad 
proteomic analysis identified 809 independent protein targets of electrophiles in mitochondria, 
with diverse metabolic and signaling roles (24).   
Effects on oxidative phosphorylation are not consistent among electrophiles, or even 
with identical chemical species in different experimental contexts. For example, 4-HNE inhibits 
respiration at cytochrome c oxidase in mitochondria isolated from rat hearts, but inhibits 
complex III more potently in rat brain mitochondria and may also inhibit NADH-linked respiration 
via α-ketoglutarate dehydrogenase (33,34). However, intact cardiac myocytes increase their 
respiration rates upon exposure to low micromolar concentrations of 4-HNE (35). Similarly, 15d-
PGJ2, which inhibits complex I in isolated mitochondria, leads to increased complex I activity in 
endothelial cells, possibly by upregulating ROS production (36). A similar pattern may emerge 
with NO2-FA: in a study on cardiac myocytes, exposure to nitro-linoleic acid precipitated mild 
uncoupling via activation of uncoupling protein 2 (UCP2) and the adenine nucleotide transporter 
(ANT), seen as an increase in oligomycin-clamped state 4 respiration, while preliminary data 
from isolated mitochondria indicate that NO2-FA inhibit respiration (31,32). These studies 
highlight the importance of assessing electrophile effects in cell and organ systems along with 
subcellular fractions. Mitochondrial ROS production is also affected by many electrophiles. In 
addition to its respiratory effects via complex I, 15d-PGJ2 induces ROS formation in intact cells, 
even at non-toxic concentrations. The mitochondrial origin of ROS was confirmed by 
dichlorofluorescein (DCF) imaging studies in endothelial and Rho0 cells and reversal of ROS 
production with rotenone (37). 4-HNE, despite having distinct effects on the respiratory chain 
from 15d-PGJ2, also initiates ROS generation by mitochondria in various cell lines (38,39). 
Importantly, pathological levels of electrophiles may also deplete mitochondrial GSH stores 
through the activity of GSTs, impairing the organelle’s antioxidant capacity (40). 
Current data suggest that the influence of electrophilic species on mitochondria can limit 
the initiation and progression of diseases whose pathogenesis involves mitochondrial 
dysfunction. 
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1.6 MITOCHONDRIA AS MEDIATORS AND MITIGATORS OF TISSUE 
RESPONSES TO METABOLIC AND INFLAMMATORY STRESS 
In addition to their critical role in ATP synthesis, mitochondria are central coordinators of stress 
responses, integrating diverse cellular signals regarding energy balance, apoptosis, oxygen 
tension, and redox balance while driving downstream signaling events.(41) The dysregulation of 
mitochondrial function observed in human diseases such as diabetes and cardiac 
ischemia/reperfusion exemplifies the importance of this regulatory ability. 
1.6.1 Metabolic stress—diabetes 
Mitochondrial dysfunction is involved in the pathogenesis of diabetes. Type 2 diabetics have 
impaired aerobic capacity at the whole-organism level, and examination of specific insulin-
resistant tissues has revealed impaired oxidative phosphorylation with decreased expression of 
respiratory chain proteins and numerous other aberrant metabolic behaviors (42). Adipose 
tissue and skeletal muscle display dramatic changes in mitochondrial morphology in diabetics, 
including smaller size and lower numbers (43). The molecular explanations for these changes 
are still under investigation, but include downregulation of PPAR-γ coactivator 1α (PGC-1α), 
which is a key activator of respiratory complex expression and mitochondrial biogenesis (42). In 
addition, muscle tissues in T2DM exhibit “metabolic inflexibility,” or an inability to switch 
between glucose and lipid oxidation, resulting in preferential uptake and oxidation of lipids and 
decreased glucose metabolism. In cardiac muscle this effect is partially mediated by activation 
of PPAR-α, likely through interactions with long-chain fatty acid ligands (44). Enhanced fatty 
acid oxidation leads to redox imbalance via an increased NADH:NAD+ ratio, which further 
inhibits glucose oxidation by impeding pyruvate dehydrogenase activity and promotes 
mitochondrial ROS formation. Mitochondrial ROS are implicated in many disease-related 
complications, including insulin resistance, microvascular dysfunction, and diabetic 
cardiomyopathy. In the latter case, one model proposes that ROS and lipid peroxidation 
byproducts lead to uncoupling protein (UCP) activation, lowering the inner mitochondrial 
membrane (IMM) potential, increasing O2 consumption, and decreasing contractile efficiency 
(45). 
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1.6.2 Cardiac ischemia/reperfusion 
Aberrant mitochondrial function is central to the pathology of cardiac 
ischemia/reperfusion injury. Severe ischemia depletes myocardial ATP, leading to ion pump 
failure and ionic imbalance, including an excess of cytosolic Ca2+ following loss of SERCA 
activity (46). The permeability transition pore (PTP) remains closed due to the low pH and low 
intramitochondrial Ca2+ concentrations during ischemia. These conditions are reversed upon 
reperfusion: pH increases and the IMM potential is restored, leading to Ca2+ influx to 
mitochondria, favoring PTP opening and ultimately apoptotic cell death (47). An additional 
injurious factor during reperfusion is ROS generation, which occurs at high levels. ROS and 
their reactive byproducts contribute to apoptosis and necrosis, as evidenced by effective 
antioxidant therapeutic interventions in animal models (48).  
Though energetic failure is a precipitating event in I/R injury, pharmacologic or 
physiologic disruption of mitochondrial metabolism is associated with cardioprotection. Electron 
transport chain inhibitors acting at each of the respiratory complexes have been shown to 
improve outcomes in I/R, and ischemic preconditioning leads to ETC inhibition at multiple levels. 
The mechanisms underlying this seemingly paradoxical effect are not well understood, but it is 
proposed that respiratory chain inhibition at the time of reperfusion weakens the accompanying 
ROS burst and Ca2+ influx to mitochondria (49). Another metabolic pathway relevant to 
cardioprotection is fatty acid oxidation. Glucose oxidation is more efficient than fatty acid 
oxidation per mole O2 consumed, a fact which becomes especially salient in situations of low O2 
supply, and which has been pharmacologically exploited: the 3-ketoacyl-coenzyme A thiolase 
inhibitor class of heart failure medications, which includes trimetazidine and ranolazine, inhibit 
FAO and shift myocardial substrate usage from fatty acids to glucose (50). The reasons for this 
change in efficiency are complex, but are due to the lower P/O ratio for fatty acid oxidation 
versus glucose oxidation, mitochondrial uncoupling (via UCP shuttling of fatty acid anions or 
activation of UCPs by ROS), and futile cycling of fatty acid metabolic intermediates (51). 
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1.7 CONCLUSION 
Mitochondria are a critical nexus of cell signaling processes in inflammation. The 
increased redox activity of mitochondria during metabolic stress and cardiac 
ischemia/reperfusion favors formation of electrophilic lipid derivatives through PUFA interactions 
with ROS and RNS. These species adduct proteins at nucleophilic cysteine, histidine, and lysine 
residues, and activate adaptive signaling pathways by regulating transcription factor activity. In 
addition, mitochondrial targets of electrophiles are numerous, and electrophiles can be 
cytoprotective in settings of mitochondrial dysfunction (NO2-FA in models of type 2 diabetes and 
cardiac I/R, for instance). The electrophile targets in mitochondria which promote protection are 
incompletely characterized, but may include respiratory chain components and UCPs 
(modulating ATP and ROS production and O2 consumption), matrix metabolic enzymes (altering 
the contribution of fatty acid oxidation to cellular bioenergetics), and apoptotic machinery. 
Improving our understanding of electrophile signaling in mitochondria will aid in the development 
of effective interventions for metabolic and inflammatory disease. 
 
1.8 HYPOTHESIS 
The overall hypothesis for the studies presented here is that electrophilic fatty acids 
generated by metabolic and inflammatory processes serve to induce adaptive tissue responses. 
More specifically, based on the information outlined above it was hypothesized that nitro-fatty 
acids covalently modify and alter the activity of respiratory chain components to induce tissue-
protective metabolic alterations.   
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2.1 ABSTRACT 
Nitro-fatty acids (NO2-FA) are metabolic and inflammatory-derived electrophiles that promote 
tissue protection in renal and cardiac ischemia-reperfusion (IR). Since drugs which inhibit 
respiratory chain function and favor glycolysis can display cardioprotective actions, it was 
hypothesized that NO2-FA impact mitochondrial electron transport and induce cardioprotective 
metabolic shifts in cells. Nitro-oleic acid (OANO2) addition inhibited complex II-linked (but not 
complex I-linked) respiration in isolated rat heart mitochondria at low µM concentrations. 
Complex II activity analysis revealed OANO2 inhibition was pH-dependent and reversible by the 
addition of the low molecular weight thiol β-mercaptoethanol (BME). Following electrophoretic 
separation of proteins from OANO2-treated mitochondria, addition of BME to the Coomassie-
stained band corresponding to the Fp subunit of complex II yielded OANO2-BME adducts by 
reverse Michael addition, revealing post-translational protein modification by OANO2. 
Extracellular flux analysis of H9C2 cardiomyoblasts confirmed the importance of respiratory 
inhibition by OANO2, as low µM concentrations of OANO2 reduced basal and maximal 
respiration and favored glycolytic metabolism. The addition of NO2-FA also induced acute 
cardioprotection in an isolated perfused heart IR model. Together these findings indicate that 
NO2-FA can promote cardioprotection by inducing a shift from respiration to glycolysis in the 
post-ischemic interval. 
2.2 INTRODUCTION 
The inflammatory stress associated with myocardial ischemia/reperfusion promotes the in vivo 
nitration of unsaturated fatty acids to yield electrophilic nitro-fatty acids (NO2-FA) (3) that 
mediate adaptive signaling actions in a variety of models of metabolic and inflammatory disease 
(52,53). Broadly and reversibly reactive with protein Cys and His residues, these compounds 
activate and deactivate diverse cell signaling cascades, acutely altering protein catalytic activity 
(GAPDH, MMP9) and ultimately modulating inflammatory and metabolic gene expression (via 
reactions with the redox-sensitive transcriptional regulatory factors Keap1/Nrf2, NF-κB, HSF, 
and PPARγ) (13,54,55). This multiplicity of targets suggests that several independent 
mechanisms underlie the beneficial effects of NO2-FA. Indeed, previous investigations 
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describing cardioprotection by NO2-FA have implicated both the suppression of NF-κB-regulated 
gene expression in an in vivo murine coronary ligation model) and inhibition of the mitochondrial 
adenine nucleotide transporter (ANT, in an isolated perfused rat heart global ischemia model) 
(3,56). 
Further interest in mitochondrial-based mechanisms of NO2-FA -mediated 
cardioprotection arises from the contributions of this organelle to fatty acid nitration, attributable 
to the proximity of reactive species formation and a convoluted membrane rich in readily-
oxidized polyunsaturated fatty acids. Separate studies have documented the generation of NO2-
FA during in vivo IR injury and in mitochondria following the cyclic hypoxia-reoxygenation 
episodes of ischemic preconditioning (3,31). Further, isolated mitochondria incubated with nitrite 
(NO2-) produce NO2-FA even under normoxic conditions, after NO2- oxidation to, nitrogen 
dioxide (.NO2) and subsequent addition to conjugated linoleic acid (57). As any in vivo 
cardioprotective role of NO2-FA would be expected to involve targets proximal their site of 
production, redox-sensitive mitochondrial proteins represent appealing candidates. 
The central role of the mitochondrion in cardiac ischemia/reperfusion injury remains an 
active area of discovery. The generation of partially reduced oxygen and nitric oxide (NO)-
derived species, their reaction with critical constituents of the electron transport chain, calcium 
overload, loss of membrane potential, changes in permeability transition pore function and 
release of cytochrome c are all central events in the cardiomyocyte death that accompanies 
reperfusion injury (48,58-61). A number of therapeutic strategies targeting each of these events 
have proven capable of diminishing infarct size in experimental models. Notably, there is a 
statistically significant relationship between compounds that inhibit respiratory metabolism and 
the promotion of cardioprotection following IR, thus structurally-diverse and mechanistically-
distinct inhibitors acting at each complex of the respiratory chain have proven effective in 
reducing infarct size (49). The predominant mechanisms underlying this phenomenon both 
remain a subject of debate, and motivate interest in identifying additional drug candidates that 
promote the metabolic shift from respiration to glycolysis. For example, high-throughput 
screening recently revealed a novel function for the FDA-approved motion sickness drug 
meclizine, which has proven cardio- and neuroprotective in IR models (62).  
As the electron transport chain is exquisitely sensitive to reactive species, we 
hypothesized that NO2-FA mediate cardioprotection, in part, through the post-translational 
modification and inhibition of respiratory chain components. Herein, complex II is established as 
a sensitive and reversible target of inhibition by NO2-FA in heart mitochondria. This led to 
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respiratory inhibition and enhancement of glycolysis in a cardiomyoblast cell line and acute 
cardioprotection in an isolated perfused rat heart model of global IR.  
2.3 EXPERIMENTAL PROCEDURES 
2.3.1 Reagents 
Nitro-oleic and nitro-linoleic acid were synthesized according to an existing method (63). Other 
chemicals were purchased from Sigma (St. Louis, MO) unless otherwise indicated.  
2.3.2 Mitochondrial isolation and respirometry 
Fresh mitochondrial isolates were obtained from rat hearts. Following anesthesia with 
isoflurane, hearts were rapidly excised from male Sprague-Dawley rats and placed into cold 
mitochondrial isolation buffer (10 mM HEPES, 250 mM sucrose, 0.2 mM EDTA). Hearts were 
minced to 2 mm slices, then placed in clean isolation buffer and washed on filter paper and 
moved to a fresh beaker containing isolation buffer and 0.1% trypsin (dissolved in 1 mM HCl). 
After stirring for 5 min, tissue was homogenized with a glass-teflon homogenizer. Following 
addition of protease inhibitor to the homogenate, it was centrifuged at 600xg and the pellet 
discarded. The supernatant was retained and centrifuged at 8000xg, the pellet washed with 
isolation buffer and again centrifuged at 8000xg. The pellet was resuspended in a minimal 
volume (~500 µl) of isolation buffer to yield a preparation of approximately 20 mg/ml protein. For 
respirometry studies, this preparation was diluted in respiration buffer (120 mM KCl, 25 mM 
sucrose, 10 mM HEPES, 1 mM EGTA, 1 mM KH2PO4, 5 mM MgCl2) in a stirred chamber 
containing a Clark-type O2 electrode. Respiratory control ratios (RCR) were determined at 1 
mg/ml final protein concentration with 8 mM malate/4 mM glutamate as substrates for state 4 
respiration and addition of 10 mM ADP to initiate state 3. Preparations with RCR values <4 were 
discarded. For NO2-FA inhibition experiments, a final protein concentration of 350 µg/ml was 
employed. OANO2 and OA were diluted from methanol stocks to final concentrations of 0-10 
µM, and incubated with mitochondria for 10 min before addition of state 4 substrates (either 8 
 31 
mM glutamate/4 mM malate or 8 mM succinate). O2 concentration in the chamber was recorded 
for 15 min and rates determined from the linear portion of the curve, after ~3 min. When 
mitochondria were used following freeze-thaw, oxidized cyt c was added just before substrate at 
300 µg/ml. When FCCP was used, it was diluted from a methanol stock to achieve a final 
concentration of 500 nM and added 5 min before addition of OANO2.  
2.3.3 Respiratory chain complex activity measurements 
Rat heart mitochondrial preparations described above (~20 mg/ml) were frozen until use. All 
activity measurements were made in the presence of 50 µg mitochondrial protein in 10 mM 
HEPES buffer containing 2.5 mM MgCl2 and 2 mM KCl. Complex II activity was determined in a 
reaction mixture (1 mL) which also contained 0.1 mM EDTA, 75 µM DCPIP, 50 µM 
decylubiquinone and 20 mM succinate, following the decrease in absorbance at 600 nm. 
Complex II+III activity was determined in the same HEPES buffer with 50 µg mitochondrial 
protein, 20 mM succinate, 50 µM decylubiquinone and 50 µM oxidized cytochrome c, by 
following the increase in absorbance at 550 nm (using an extinction coefficient of 21 mm-1cm-1. 
In experiments where mitochondria were incubated with OANO2 or OA before centrifugation and 
resuspension, preparations were incubated with 10 µM fatty acid in buffer at pH 9.0 for 10 min, 
followed by centrifugation at 14,000 x g. In some cases, 1 mM BME was added for an additional 
10 min before centrifugation. The supernatant was discarded, the pellet resuspended at pH 7.4, 
and complex activity determined under the conditions described above. 
2.3.4 Respiratory chain complex protein analyses 
Blue native gel electrophoresis resolution of mitochondrial respiratory complexes was performed 
as described (64) with minimal modification. 400 µg of rat heart mitochondrial protein was 
treated with 0 or 20 µM OANO2, extracted with lauryl maltoside and separated by tricine-SDS-
PAGE. Because of the sensitivity of Complex II to inhibition by fatty acid nitroalkenes, the band 
corresponding to complex II was a primary subject of focus.  It was excised, sliced into 2 mm 
segments, and incubated in 200 ul ACN for 10 min at 25oC. ACN was removed and the gel 
pieces dried under vacuum while being centrifuged for 10 min, followed by rehydration in 50 mM 
phosphate buffer (pH 8.0) containing 500 mM BME for 1 h at 37oC. Then, pH was adjusted to 
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5.0 with 1 M formic acid to quench trans-nitroalkylation reactions. BME-electrophilic lipid 
adducts were determined in the buffer by LC/MS, following the neutral loss of BME from the 
adduct as described (65). In denaturing gels, identification of the 70 kDa subunit was performed 
by Western blot following SDS-PAGE of 40 µg mitochondrial protein treated with 0, 5, or 10 µM 
OANO2. Identically loaded gel lanes were excised, one set for Coomassie stain and one for WB 
analysis. Following transfer of the WB gel to a PVDF membrane and blocking with 5% milk, a 
mouse monoclonal antibody (Mitosciences, Eugene, OR) against the 70 kDa Fp subunit was 
added at 1:2000 dilution in TTBS. After washing, an HRP-conjugated anti-mouse Ig antibody 
(Cell Signaling Technologies, Danver, MA) was added at 1:5000, and film was developed 
following addition of ECL reagents after additional washing. The Coomassie stained bands 
corresponding to the 70 kDa subunit were excised, sliced into 2 mm segments, and incubated in 
200 ul ACN for 10 min at 25oC. ACN was removed and the gel pieces dried under vacuum while 
being centrifuged for 10 min, followed by rehydration in 50 mM phosphate buffer (pH 8.0) 
containing 500 mM BME for 1 h at 37oC. pH was adjusted to 5 with 1 M formic acid to quench 
trans-nitroalkylation reactions. BME adducts were determined in the buffer by LC/MS, following 
the neutral loss of BME from the adduct as described (65) with minor modifications. 
2.3.5 Extracellular flux analysis in H9C2 cells 
H9C2 cells (ATCC, Manassas, VA) were maintained in DMEM (Mediatech, Manassas, VA) with 
10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 ng/ml streptomycin (Invitrogen, 
Carlsbad, CA), and used between passages 17 and 30. For extracellular flux (XF) analysis, cells 
were plated at 20,000 per well in specialized Seahorse 24-well plates and left to adhere and 
grow overnight. The next day media was exchanged for DMEM supplemented with 25 mM 
glucose, 4 mM L-glutamine, and 1 mM pyruvate (600 µl final volume per well) 90 min prior to the 
start of assay. Compounds for injection in the Seahorse analyzer were diluted into this medium 
at 10x final concentration and pipetted into the injection ports on the cartridge at appropriate 
volumes for 10x dilution (66 µl for port A, 73 µl for port B, etc.); other treatments were 
administered 90 min prior to XF analysis where indicated. A Seahorse XF24 analyzer (Seahorse 
Bioscience, North Billerica, MA), which allows real-time determinations of O2 and proton 
concentrations in a transient 7 µl chamber in each well of the plate (66), was employed to 
simultaneously determine glycolytic and respiratory flux. Data are expressed as either pmol/min 
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(for O2 consumption), mpH/min (for extracellular acidification), or as percentage of basal rate of 
either of these parameters. 
2.3.6 Isolated, perfused Langendorff heart preparations 
Hearts were rapidly excised from male Sprague-Dawley rats following induction of anesthesia 
with ketamine/xylazine (80 mg/kg and 5 mg/kg), and perfused in retrograde as described (67). 
The perfusate was KH buffer containing 20 mM glucose, 118 mM NaCl, 4.7 mM KCl, 1.2 mM 
MgSO4, 1.25 mM CaCl2, 1.2 mM KH2PO4, and 25 mM NaHCO3, equilibrated with 95% O2, 5% 
CO2 gas. Coronary flow was held constant at 8-12 mL/min at 37oC. Hearts were equilibrated for 
30 min before insertion of a balloon to the left ventricle, which was inflated to allow left 
ventricular developed pressure (LVDP) to be measured by a force transducer. Hearts which 
failed to surpass exclusion criteria (outlined elsewhere (67)) were discarded. Then, 15 min after 
balloon insertion 100 nM LNO2 or vehicle (methanol, at 1/1000 final dilution) were infused for 15 
min just above the heart using a syringe pump. At the end of this interval, hearts were subjected 
to 35 min of no-flow ischemia, maintained at 37oC in the perfusate buffer. Flow was restored 
slowly to the original rate over 5 min to initiate reperfusion, and LVDP and heart rate recorded 
for 60 min.  
 
2.3.7 Statistical analysis 
 
Where appropriate, Student’s t test or analysis of variance were applied to the data, with p < 
0.05 used as the cutoff for significance. 
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2.4 RESULTS 
2.4.1 Nitro-fatty acid inhibition of O2 consumption by isolated mitochondria 
Electrophile effects on respiratory chain components are varied, with some electrophiles 
targeting multiple complexes and other electrophiles preferentially modifying distinct 
proteins (68,69). To first define the effects of a fatty acid nitroalkene on overall respiratory 
metabolism, isolated rat heart mitochondria were preincubated with low µM concentrations 
of OANO2 or oleic acid (OA) with substrates supporting either complex I- or II-linked 
respiration. No inhibition of respiration was observed by up to 10 μM OANO2 concentrations 
in the presence of the complex I-linked substrates malate and glutamate (Figure 4A).  In 
contrast, significant inhibition of succinate-mediated respiration was observed at 3 μM 
OANO2. This concentration also induced an initial phase of rapid respiration upon addition of 
succinate, but this was not sustained and ultimately a linear rate of O2 consumption only 
~30% of control was achieved (Figure 4b). Inhibition of complex II-linked respiration could 
be reversed by the addition of ascorbate/TMPD, substrates which donate electrons to 
complex IV via cytochrome c (Figure 18, Appendix A). Together, these data suggest that 
complex II is a target of NO2-FA. One freeze-thaw cycle was sufficient to eliminate the effect 
of OANO2 on succinate-linked respiration having added cytochrome c (Figure 5A). 
Pretreatment with the uncoupling agent FCCP blunted the inhibitory effect of OANO2 (Figure 
5B). Thus, the respiratory state influenced the ability of OANO2 to inhibit complex II-linked 
respiration. 
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Figure 4. NO2-FA inhibition of complex II-linked respiration. Freshly isolated rat heart 
mitochondria (0.5 mg, all RCR > 4) were incubated in respiration buffer (pH 7.2) for 5 min with 
OANO2 (0-10 μM) prior to substrate addition. a) Representative O2 concentration traces 
following addition of the complex I-linked substrates glutamate (8 mM) and malate (4 mM) 
(upper panel). Average rates from three independent experiments ± SD (lower panel). b) O2 
concentration traces following succinate (10 mM) addition (upper panel). Rates for bar graph 
(lower panel) were taken from the linear portion of the each trace (n=3, mean ± SD); *, p < 0.05 
by one-way ANOVA, versus 0 μM OANO2. 
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Figure 5. Effect of uncoupling on inhibition by NO2-FA. a) Mitochondria, following one 
cycle of freeze-thaw, were supplied with 50 μM cytochrome c and incubated with 0 or 10 
μM OANO2 for 5 min before addition of 10 mM succinate. Values represent the linear O2 
consumption rates following succinate addition (n=3, mean ± SD). b) Freshly isolated 
mitochondria were exposed to 0 or 500 nM FCCP prior to 5 min of incubation with 10 
μM OANO2. O2 consumption rates were determined following addition of 10 mM 
succinate (n=3, mean ± SD); *, p < 0.05 by Student’s t test, two-tailed. 
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 2.4.2 Inhibition of complex II activity by nitroalkenes is reversible and pH-
dependent 
Given that interventions which uncouple mitochondria (FCCP, freeze-thaw) led to a loss of 
respiratory inhibition by OANO2, and that the availability of the Cys thiolate for Michael addition 
reactions is greater at high pH, the maintenance of a high matrix pH may be necessary for 
OANO2 binding to its target residue. Preliminary experiments indicated that inhibition of complex 
II activity at pH 7.4 by OANO2 was modest relative to the effects on succinate-linked respiration. 
To assess the pH-dependence of OANO2 inhibition of complex II, complex II+III activity was first 
assayed in mitochondria subjected to a freeze-thaw cycle, followed by addition of 10 μM OANO2 
or OA over a range of pH values. While OANO2 did not alter activity at pH 6.5 relative to control, 
inhibition became more pronounced with increasing pH, with a maximum inhibition of 82% 
reached at pH 9.0 (Figure 6). 
Activity of complex II alone was not measured over this pH range, as the assay was 
sensitive to high pH values. Thus, to ensure that the observed inhibition was due to a loss of 
complex II activity, thawed mitochondria were incubated with OANO2 or OA at pH 9.0, 
sedimented by centrifugation and resuspended in buffer at pH 7.4. Independent activity assays 
for complex II and complex III were then conducted. While complex II activity was significantly 
inhibited by OANO2 (~80%, Figure 7a), complex III activity was unchanged (Figure 7b), 
confirming that complex II is the target of pH-dependent respiratory inhibition by OANO2. 
If the nitroalkene inhibition of complex II is a redox signaling event, this would be better 
facilitated if the Michael addition reaction were reversible. In this regard, the low molecular 
weight thiol β-mercaptoethanol (BME, 1 mM, pH 9.0) to OANO2–treated mitochondria fully 
reversed the loss of complex II+III activity to levels reflective of untreated controls (Figure 8). 
This concentration of BME had no effect on the respiratory activity of mitochondria treated with 
native OA. It was concluded that OANO2 inhibits complex II by thiol-reversible Michael and that 
the state-dependence of respiratory inhibition in freshly isolated mitochondria may be due to 
changes in matrix pH.  
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Figure 6. pH dependence of complex II inhibition by NO2-FA. a) Following freeze-thaw, 50 
μg of mitochondrial protein was incubated with 10 μM OA or OANO2 at varied pH and 
assayed for complex II+III activity. Data represent first order rates over 240 s (n=3, mean ± 
SD). b) Mitochondria incubated with OA or OANO2 at pH 9.0 for 10 min were pelleted by 
centrifugation, resuspended and assayed for complex II (upper panel) or complex III (lower 
panel) activity. All data represent n=3, mean ± SD; *, p < 0.05 by Student’s t test, two-tailed, 
versus OA. 
 
 
 
 
 
 
 39 
 
Figure 7. Complex II inhibition by NO2-FA is reversed by low molecular weight thiols. 
Mitochondria treated with OA or OANO2 at pH 9.0 were subsequently incubated with +/-1 mM 
BME, centrifuged, washed, and resuspended at pH 7.4. Complex II+III activity was then 
determined (n=3, mean ± SD for all groups); *, p < 0.05, one-way ANOVA. 
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Figure 8. NO2-FA modify complex II. 400 μg of mitochondrial protein from frozen stocks 
was incubated with 0 or 20 μM OANO2, and respiratory complexes were solubilized with 
lauryl maltoside and separated by blue native PAGE. The complex II band was removed, 
dried with ACN and rehydrated with 500 mM BME. a) A representative blue native gel, with 
the band corresponding to complex II is highlighted. b) LC/MS profile of the BME-OANO2 
adducts observed in control and 20 μM OANO2-treated conditions, with a 13C internal 
standard shown. 
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2.4.3 Nitro-fatty acids directly modify the Fp subunit of complex II 
The pH-dependence and thiol reversibility of complex II inhibition suggested that NO2-FA modify 
Cys or His residues in this complex by Michael addition. Because other thiol-reactive species 
such as ONOO-, nitroxyl, and HNE mediate inhibition of complex II through oxidation or 
adduction of critical cysteine residues on the catalytic 70 kDa Fp subunit (70-72), it was 
hypothesized that NO2-FA would also modify this protein. To test this concept, a trans-
nitroalkylation reaction to capture protein-adducted thiols was first employed (65). Mitochondrial 
lysates were incubated with OANO2 (0-20 μM), proteins were denatured and then separated by 
SDS-PAGE. Following Coomassie staining, the band corresponding to the Fp subunit of 
complex II was confirmed by Western blot analysis and obtained. This was incubated with BME 
(500 mM) and BME-OANO2 adducts representing previously protein-bound OANO2 were 
determined by LC/MS, monitoring the neutral loss of BME from the adduct. No BME-OANO2 
adducts were observed in controls, while OANO2 dose-dependent increases in the area of the 
404/326 transition were observed, indicating that the Fp subunit of complex II is directly 
adducted by OANO2 (Figure 9). 
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Figure 9. NO2-FA directly modify the Fp subunit of complex II. 100 μg of mitochondrial 
lysate was incubated with 0, 5 or 20 μM OANO2, followed by SDS-PAGE and protein labeling by 
Coomassie stain. The band corresponding to the 70 kDa subunit of complex II was removed, 
dried with ACN and rehydrated in the presence of 500 mM BME. a) A representative 
Coomassie-stained gel, with the 70 kDa Fp subunit highlighted. b) Peak areas for BME-OANO2 
adducts at 0, 5, and 20 μM OANO2. n=3 per group, mean ± SD. 
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2.4.4 Nitro-fatty acids induce metabolic shifts in cardiac muscle cells. 
Alterations in respiratory metabolism are associated with cardioprotection in models of 
ischemia-reperfusion (49). To determine if the effects of NO2-FA observed in isolated 
mitochondria occurred intact cells, H9C2 cardiomyoblasts were underwent metabolic analysis 
using a Seahorse XF24 analyzer. The O2 consumption rate (OCR, representing respiratory 
activity) and the extracellular acidification rate (ECAR, reflective of glycolytic flux) were 
simultaneously measured and the effect of OANO2 on a variety of bioenergetic parameters was 
determined using a previously described profiling approach (73). Basal respiration, O2 
consumption due to proton leak, and maximal respiration were determined following a 2 h 
incubation with low µM OANO2 and OA concentrations. Basal and maximal respiration were 
significantly inhibited at low concentrations of OANO2, while proton leak was unaffected (Figure 
10a). 
Separately, the acute effects of OANO2 on OCR were observed by addition of 10 μM 
OANO2 to basally respiring cells. This concentration lead to a ~30% decrease in OCR over 15 
min (Figure 10b). Notably, this decrease in OCR was followed by an increase in ECAR, 
supporting that cells shifted from respiratory to glycolytic metabolism in response to respiratory 
inhibition by OANO2. Because these effects mirrored those observed in isolated mitochondria, it 
was hypothesized that uncoupling mitochondria and lowering matrix pH may also abrogate 
respiratory inhibition by OANO2 in intact cells. Myoblasts exposed to 500 nM FCCP displayed a 
60% increase in basal OCR and was not influenced addition of 10 μM OANO2 (Figure 10c). This 
supports the concept that pH-dependent modification of respiratory components impacts the 
extent of OANO2-mediated cellular respiratory inhibition. 
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Figure 10. NO2-FA inhibit respiration and promote glycolysis in H9C2 cells. O2 
consumption and extracellular acidification rates (OCR and ECAR) were measured in H9C2 
cells in unbuffered DMEM by a Seahorse XF24 analyzer. a) Following 2 h of incubation with 0-5 
μM OANO2, basal OCR was measured, followed by proton leak, maximal respiration, and non-
mitochondrial O2 consumption (induced by oligomycin, FCCP and 2-DG, and antimycin A, 
respectively). A representative experiment is shown. b) 10 μM OANO2 was added to respiring 
cells and the change in OCR and ECAR recorded. c) Addition of 10 μM OANO2 after uncoupling 
of respiration with 500 nM FCCP. For all experiments, n=5 wells per group, mean ± SD. 
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2.4.5 Nitro-fatty acids are cardioprotective in an ex vivo cardiac ischemia-
reperfusion model 
Because compounds which shift cellular metabolic activity from respiration to glycolysis are 
often protective in ischemia-reperfusion injury and some complex II inhibitors can induce 
cardioprotective effects, the influence of fatty acid nitroalkenes on cardiac function was 
evaluated in a Langendorff-perfused heart model. For this, 100 nM LNO2 or LA was 
administered for 15 min prior to induction of no-flow ischemia. Following 35 min of ischemia, 
flow was restored for 1 h, during which recovery of cardiac output (rate-pressure product, 
RPP) was monitored. Heart rate, coronary flow, and LVDP were all unaffected by LNO2 
administration prior to ischemia. RPP recovery in LNO2-treated hearts was significantly 
greater than that of LA-treated hearts during the reperfusion interval (Figure 11). 
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Figure 11. NO2-FA preserve myocardial function ex vivo after global ischemia. Following 
15 min of equilibration, a pressure balloon was inserted into the left ventricle, and pressure 
changes measured by a force transducer. Rate pressure product (RPP) was determined as the 
product of heart rate and LV developed pressure. The data represents the recovery of RPP 
following 35 min global, normothermic ischemia. All data points n=6, mean ± SD; **, p < 0.01, 
for Student’s t test versus vehicle control at the time point indicated. 
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2.5 DISCUSSION 
Nitroalkene fatty acid derivatives are generated by mitochondria and specifically in the heart by 
the metabolic stress induced by ischemia-reperfusion (31,74).  These species, when added as 
synthetic homologs, mediate myocardial protection in IR (65,74). We therefore sought to define 
the predominant mitochondrial respiratory chain effects of NO2-FA and whether this may 
contribute to the cardioprotective actions of electrophilic fatty acids. In this study complex II is 
established as the major respiratory chain target of in isolated mitochondria, and intact 
cardiomyoblasts were sensitive to respiratory inhibition by these compounds at similar 
concentrations. Further, consistent with previous reports of cardioprotection, NO2-FA 
pretreatment preserved contractile function in an ex vivo model of acute IR.  
The evidence for a link between respiratory inhibition and cardioprotection in IR is 
extensive, though it is not well defined whether a common protective mechanism unites the 
inhibition of each complex (49). Similarly, while many site II inhibitors with distinct sites of action 
are protective in IR, the involvement of this complex in protection is incompletely understood. 
Complex II inhibitors noted for their therapeutic efficacy in IR include malonate (a competitive 
inhibitor at the active site), TTFA and atpenin A5 (inhibitors of the quinone binding site), 
diazoxide (a noncompetitive inhibitor whose binding site is unknown), and 3-nitropropionate (3-
NP, a suicide inhibitor at the active site) (75-78).  In all cases, these inhibitors can display 
systemic toxicity as opposed to electrophilic nitroalkenes which have been administered for up 
to 12 weeks in murine models of vascular disease with no apparent adverse effects (53). 
A shared mechanism of cardioprotection for these structurally diverse inhibitors is 
appealing, and several candidates have been proposed. A mitochondrial KATP channel of 
undetermined molecular identity is activated by many complex II inhibitors and is considered 
crucial in preconditioning, with complex II proposed to have a structural role in this channel. 
Nitroxyl (HNO) is a thiol-modifying compound which inhibits complex II and activates the 
mitoKATP channel, promoting cardioprotection when administered prior to ischemia (71,79). 
While the potential role of this channel in NO2-FA-mediated cardioprotection was not directly 
addressed, protection of primary ventricular myocyte cultures by LNO2 in simulated IR was not 
reversible by the mitoKATP inhibitor 5-hydroxydecanoate (31). Independent of mitoKATP effects, 
complex II inhibition also leads to the modulation of superoxide and secondary species by 
complexes I and III, and an increase in partially reduced oxygen species from complex III is 
viewed to promote myocardial protection through stress kinase modulation (80,81). Either in 
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tandem with or separately from these mechanisms, the promotion of glycolytic metabolism over 
cellular respiration can also be a result of complex II inhibition that promotes cell survival in IR 
(62). While effects of NO2-FA on ROS generation was not explored herein, cells treated with low 
µM OANO2 shifted to glycolytic metabolism, providing another potential mechanism of tissue 
protection by NO2-FA in cardiac IR. This event is unique, given the abundance of regulatory 
thiols in glycolytic enzymes and the observation that GAPDH is a target in vivo for inhibition by 
electrophiles (54). In aggregate, this data may also suggest that fatty acid trafficking favors the 
modification of mitochondrial over cytosolic proteins by nitroalkenes.  
Notably, 3-nitropropionate undergoes oxidation by the 70 kDa Fp subunit flavin to yield 
the electrophile 3-nitroacrylate, the reactive metabolite of 3-NP which inhibits complex II upon 
Michael addition (82). Despite the structural and mechanistic similarities between fatty acid 
nitroalkenes and the 3-carbon nitroalkene 3-nitroacrylate, addition of 3-NP at 10-fold molar 
excess did not inhibit OANO2 binding to the Fp subunit, likely indicating that these compounds 
target different nucelophilic amino acids (Figure 17, Appendix A) (83,84). This may be explained 
by steric hindrance inherent in the bulkier 18 carbon OANO2 acyl chain that might prevent 
access to 3-nitroacrylate-reactive centers. A distinct site of modification from 3-NP may be of 
toxicological significance, since the latter causes pronounced neurogenerative responses in 
animal models independent of its cardioprotective effects (85). The apparent reversibility of 
NO2-FA adduction of complex II by low molecular weight thiols is another important 
distinguishing feature, as 3-NP adducts are considered irreversible (82). 
An earlier study linked acute cardioprotection by OANO2 to mild uncoupling induced by 
nitroalkylation of the adenine nucleotide transporter (ANT1) in mitochondria (56). However, this 
study used biotinylated NO2-FA, whose intracellular metabolism and trafficking differs from that 
of the native fatty acid, to demonstrate ANT1 modification in isolated perfused hearts. These 
trafficking differences are salient when studying the modification of mitochondrial proteins by 
NO2-FA, as the entry of fatty acids to the mitochondrion requires the addition of carnitine and 
CoA to the carboxylate. In addition, mitochondrial beta oxidation of NO2-FA generates shorter 
chain electrophilic species that may have different targets than the parent compound, with 
biotinylated NO2-FA not subject to this metabolic pathway (86). Finally, the addition of biotin 
greatly increases the size of the fatty acid and may lead to modification of proteins and residues 
distinct from unmodified NO2-FA, with the differences in binding sites of 3-nitroacrylate and 
OANO2 above underscoring the importance of structural differences in nitroalkene signaling.  
Additional insights from the present study in the context of previous reports of the 
mitochondrial effects of NO2-FA include the observation of uncoupling and the concentrations 
 49 
used to elicit respiratory inhibition. In one study, a small (though significant) increase in O2 
consumption rate was noted by extracellular flux analysis in H9C2 cells at 1 µM LNO2 (56). This 
was a minor effect relative to previous data showing robust uncoupling of primary rat ventricular 
myocytes at concentrations between 0.25 and 1 µM LNO2, and in isolated mitochondria at 
concentrations up to 10 µM, with 20 µM required for inhibition (31). Herein, increased respiration 
in OANO2-treated cardiomyoblasts relative to controls was not observed unless added acutely 
at high >10 µM nitroalkene concentrations, which may be due to uncoupling or metabolism of 
the fatty acid. Similarly, while transient OANO2–induced iincreases in respiration were observed 
in isolated mitochondria at low µM concentrations, respiratory inhibition then occurred within 
seconds. These previous studies used a synthetic strategy for LNO2 or OANO2 that yields a 
mixture of regioisomers (9-nitro-9-cis-octadecenoic and 10-nitro-9-cis-octadecenoic acids, in the 
case of OANO2) (87), whereas the present study used a stereospecific synthesis giving pure 10-
nitro-9-cis-octadecenoic acid (63). Other variables such as the timing of compound 
administration before analysis and the determination of NO2-FA stock concentrations may also 
influence cellular and in vitro responses observed at particular doses (57). In summary, previous 
studies have provided significant perspective and a further understanding of the dose-
dependence of bioenergetic fatty acid nitroalkene derivative effects in vivo will require further 
investigation.  
The present data indicates that inhibition of complex II by NO2-FA may depend in part on 
matrix pH, since respiratory coupling was an apparent requirement for inhibition in both isolated 
mitochondria and cells. The dissipation of the proton gradient in uncoupled mitochondria tends 
to decrease matrix pH as protons diffuse back from the intermembrane space, lowering the 
availability of thiolate anion for nitroalkylation by NO2-FA on target proteins. Consistent with this, 
inhibition of complex II+III activity by NO2-FA in isolated mitochondria after freeze-thaw was 
strongly dependent on pH, with maximal inhibition occurring near pH 9.0. The pH-dependent 
response of respiratory inhibition by OANO2 suggests that modification of a thiol on complex II 
with a pKa of approximately 8.0 is responsible for NO2-FA-mediated inhibition. Estimates of in 
vivo matrix pH using pH-sensitive GFP mutants indicates that this compartment in resting 
cardiomyocytes maintains ~pH 7.9, and a higher local pH would be expected near the 
respiratory complexes, where protons are actively exported from the matrix (88). Thus, changes 
in matrix pH are a plausible mechanism accounting for the effect of uncoupling on fatty acid 
nitroalkene-induced respiratory inhibition. 
The administration of nitrite mediates the post-translational modification of complex I 
thiols and leads to cardiac protection from ischemic insult (89). Herein, there was no effect of 
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OANO2 on NADH-linked respiration in isolated mitochondria. This is consistent with an earlier 
report that reported no effect of LNO2 on complex I activity (31). Why complex I is susceptible to 
inhibition by S-nitrosation and not S-nitroalkylation is unclear, but there is a precedent in that a 
number of reactive species display a predilection toward complex II cysteines. For example, a) 
Cys90 in the Fp subunit of bovine complex II (corresponding to Cys81 in the rat) is S-
glutathionylated in vitro upon addition of oxidized glutathione GSSG, b) the loss of S-
glutathionylation in rat hearts occurs during IR–induced cardiac injury and allied succinate 
dehydrogenase inhibition (90) and nitroxyl preferentially inhibits complex II over complex I (71). 
Inhibition of complex II in heart mitochondria by the electrophile 4-HNE has also been reported, 
with modification of the Fp subunit observed by Western blot (72). 
Signaling by individual electrophilic species involves effects on multiple protein targets in 
various cellular compartments, and it is likely that several mechanisms account for the acute ex 
vivo cardioprotection conferred by NO2-FA. Overall our data support a role for respiratory 
inhibition in the cardioprotective mechanism of NO2-FA, likely via inhibition of complex II, 
promoting glycolysis and preserving myocardial function in the post-ischemic interval. 
Endogenous production of fatty acid nitroalkenes during ischemic stress thus serves to link 
inflammatory stress with beneficial metabolic responses, a pathway which their pharmacological 
administration may exploit. 
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3.1 ABSTRACT 
Nitro-fatty acids (NO2-FA) are electrophilic signaling mediators whose nitroalkene moiety 
enables reactivity with nucleophilic amino acid residues. Metabolism of NO2-FA occurs by 
reduction to non-electrophilic nitroalkanes (by prostaglandin reductase-1 (PGR1)), 
mitochondrial β-oxidation, and protein adduction, though the relative contributions of these 
mechanisms to inactivation of NO2-FA are unclear. An LC/MS-based approach allowed 
measurement of these metabolic reactions in H9C2 cardiomyoblasts and isolated perfused 
rat hearts. Inhibitors of PGR1 (indomethacin) and β-oxidation (etomoxir) revealed the 
contributions of these pathways to NO2-FA metabolism and signaling. Additionally the effect 
of hypoxic conditions on reduction versus oxidation reactions was determined. 
Indomethacin preserved nitro-oleic acid (OANO2) levels in the media of treated cells and 
abrogated the reduction of OANO2 in isolated hearts, enabling increased downstream 
chemical and signaling reactions (thiol adduction and HO-1 expression). Etomoxir 
decreased the generation of shorter chain nitroalkenes and increased the levels of reduced 
metabolites. Hypoxic conditions in isolated and perfused ischemic hearts also increased 
reduction and reduced β-oxidation of OANO2.  In summary, inhibition of PGR1-mediated 
metabolism of NO2-FA enhances electrophilic thiol adduction signaling, preventing 
saturation of the nitroalkene double bond. 
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3.2 INTRODUCTION 
Fatty acid-derived electrophiles, including α,β-unsaturated ketone and nitroalkene derivatives, 
engage multiple adaptive signaling pathways and induce protective tissue responses in 
inflammatory pathologies (91). Nitro-fatty acids (NO2-FA) in particular have cardioprotective 
activity in ischemia-reperfusion injury in vivo, ex vivo, and in cell-based models (3,56). Several 
mechanisms of action have evolved to transduce these beneficial effects of nitro and other 
electrophilic fatty acids in myocardial injury, including mitochondrial complex II inhibition, 
promoting a shift to glycolytic metabolism, respiratory uncoupling via the adenine nucleotide 
transporter (ANT1), and inhibition of NF-κB (56,74,92). Each of these diverse NO2-FA-mediated 
signaling mechanisms relies fundamentally on the availability of either the parent nitroalkene or 
its electrophilic metabolites to modify cysteine residues on target proteins. 
NO2-FA are subject to a variety of metabolic reactions in vivo including β-oxidation, 
saturation by prostaglandin reductase-1 (PGR1), non-enzymatic adduction to proteins by 
Michael addition (thereby facilitating signaling activity), and conjugation to glutathione (86). 
PGR1 reduction and glutathione conjugation deactivate the electrophilic functionality of NO2-FA, 
while β-oxidation leads to the formation of shorter electrophilic species, apparently unable to 
proceed past the position of the nitro group to remove the electrophilic moiety (86). The 
importance of these catabolic reactions in determining the potency and efficacy of NO2-FA 
signaling is further characterized herein.  
By inhibiting the metabolism of active signaling mediators, pharmacokinetics can be 
modulated to allow administration of lower and/or less frequent doses and providing an 
alternative to chemically modifying the parent compound. For example, the plasma half-life of 
peptide therapeutics may be extended by peptidase inhibitors (93). The recent emergence of 
electrophilic inflammatory modulators as potential therapeutics, such as bardoxolone methyl for 
treating chronic renal disease, suggests that other electrophilic compounds may also be of 
clinical utility (94). In this regard, it becomes important to understand mechanisms of 
electrophile inactivation and metabolism. 
PGR1, which reduces the double bond proximal to the nitro group in NO2-FA to form 
non-electrophilic nitroalkanes (95), is present in most mammalian tissues and is inhibited by 
cyclooxygenase (COX) inhibitors at a Ki for PGR1 that is ~50x lower than for COX (96). 
Recently, siRNA knockdown of transfected PGR1 was observed to limit nitroalkene reductase 
activity human embryonic kidney cells (95). Based on these data, it was hypothesized that 
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indomethacin pretreatment would enhance NO2-FA signaling in the heart by preventing the 
inactivation of the electrophilic nitroalkene moiety. Also, β-oxidation results in the formation of 
shorter chain NO2-FA, which may have a distinct signaling behavior compared with the parent 
compound, or be more or less susceptible to inactivation by PGR1. An agent that blocks β-
oxidation, such as the carnitine palmitoyl transferase 1 (CPT1) inhibitor etomoxir, may therefore 
also impact signaling by NO2-FA.  
Of particular relevance to electrophile signaling during cardiac ischemia-reperfusion, 
redox changes associated with hypoxia may also influence NO2-FA metabolism, since a) β-
oxidation is inhibited by hypoxia and b) reducing equivalents such as NADH accumulate (97). 
Notably, NADPH, which is a cofactor for PGR1-mediated NO2-FA reduction, can be depleted in 
cardiac tissue under low oxygen conditions via reactions that can also suppress reduced 
glutathione and protein thiol pools (97,98). In aggregate, these circumstances may enhance 
NO2-FA availability or modulate other signaling responses and warrants evaluation. 
In this study a targeted metabolic profiling approach is employed to determine the effects 
of pharmacological inhibitors and a physiological perturbation, hypoxia, on NO2-FA metabolism 
and signaling activity in cardiomyoblasts and isolated perfused rat hearts. 
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3.3 EXPERIMENTAL PROCEDURES 
3.3.1 Reagents 
Nitro-oleic acid and its 13C internal standard were synthesized according to an existing method 
(63). Solvents for extractions and HPLC/ESI-MS/MS were purchased from Burdick and Jackson 
(Muskegon, MI). Other chemicals were purchased from Sigma (St. Louis, MO) unless otherwise 
indicated.  
3.3.2 Langendorff-perfused heart preparation 
Hearts were rapidly excised from male Sprague-Dawley rats following induction of anesthesia 
with isoflurane, and perfused in retrograde as described (67). The perfusate was KH buffer 
containing 20 mM glucose, 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.25 mM CaCl2, 1.2 
mM KH2PO4, and 25 mM NaHCO3, equilibrated with a gas mixture of 95% O2, 5% CO2. 
Coronary flow was held constant at 8-12 mL/min at 37oC. In experiments where indomethacin 
was used, it was diluted to 200 µM in 1 L of perfusate buffer in 1 mL dimethylsulfoxide (DMSO). 
In control experiments 1 mL DMSO was added to the perfusate as vehicle. Hearts were 
equilibrated for 30 min before infusion of OANO2 (5 µM final concentration) or vehicle 
(methanol, at 1/1000 final dilution) via a syringe pump just above the heart. Infusion was 
maintained for 15 min followed by 30 min washout, and effluent fractions collected during this 
period. Following washout, hearts were flash-frozen in liquid N2 for later analysis.  
3.3.3 Metabolite extraction from heart and NEM displacement of protein adducts 
For extraction of OANO2 and its metabolites, a protocol previously described for the analysis of 
phospholipids was employed (99). Briefly, 100 mg heart tissue was mechanically ground to 
homogeneity in 1 ml PBS using a Tekmar Tissumizer (Cincinnati, OH). Protein concentration 
was determined by BCA assay (Pierce, ThermoFisher, Rockford, IL), and adjusted to 20 mg/ml 
with PBS, after which 1 ml of homogenate was transferred to a glass tube for extraction. 2.5 ml 
of a lipid extraction solvent consisting of 30% hexane, 20% isopropanol and 2% formic acid was 
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added to the homogenate and the mixture vortexed for 30 s. 2.5 ml hexane was then added 
followed by vortexing for an additional 30 s. To separate phases, this mixture was centrifuged at 
2,000 rpm for 5 min. The upper hexane fraction was removed, dried in a RapidVap (Labconco, 
Kansas City, MO), resuspended in 500 µl MeOH, and transferred to a vial for LC/MS analysis. 
For determination of protein-adducted electrophiles, initial tissue homogenates were split into 
two fractions, and one treated with 20 mM N-ethylmaleimide (NEM) for 1 h at 37oC. Following 
the incubation, 13C-labeled internal standard for OANO2 was added to each sample and hexane 
extraction performed as above.  
3.3.4 Liquid chromatography/mass spectrometry (LC/MS) determination of nitro-
fatty acid metabolites 
Lipid extracts were applied to a reverse phase HPLC column (2 x 20 mm C18 Mercury column, 
Phenomenex, Torrance, CA) for resolution of OANO2 and its metabolites, with a gradient 
consisting of solvents (A): H2O with 0.1% HOAc and (B): acetonitrile with 0.1% HOAc at a flow 
rate of 0.75 ml/min. 10 µl of sample was applied to the column at 11% B (1 min) and eluted with 
a linear increase in B (11-100% in 6 min), followed by 1 min washing with 100% B and re-
equilibration for 1.5 min at 11% B. Analytes were quantified by electrospray ionization tandem 
mass spectrometry ESI-MS/MS (API4000 or AB5000 triple quadrupole mass spectrometer, 
Applied Biosystems, San Jose, CA) in the negative ion mode using multiple reaction monitoring 
(MRM).  
3.3.5 Metabolite determination in H9C2 cardiomyoblasts 
H9C2 cells (ATCC, Manassas, VA) were maintained in DMEM (Mediatech, Manassas, VA) with 
10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 ng/ml streptomycin (Invitrogen, 
Carlsbad, CA), and used between passages 17 and 30. For metabolite analysis, cells were 
plated at 200,000 per well in 6 well plates and left to adhere and grow overnight in 2 ml of 
media. The following day media was exchanged and wells were treated with 50 µM etomoxir 
(diluted from aqueous stock), 50 µM indomethacin (diluted from DMSO stock), or the 
corresponding vehicle. All wells (except 3 reserved as untreated controls) were then treated with 
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2.5 µM OANO2. 200 µl of media was removed and added to 800 µl methanol after 0, 30, 60, and 
90 min of OANO2 treatment, and at the time of cell harvest (24 h).  
3.3.6 SDS-PAGE, Western blot for HO-1 and actin 
After 24 h of treatment with OANO2, cells were lysed in 200 µl RIPA buffer, centrifuged at 
14,000 rpm for 5 min and supernatant protein determined by BCA assay. 20 µg of protein per 
well were separated by SDS-PAGE, followed by semi-dry transfer to PVDF membrane. The 
membrane was probed with a monoclonal anti-HO-1 antibody (Enzo Life Sciences, 
Farmingdale, NY) in 5% milk/TBST, dilution 1:1000. After washing, secondary antibody (anti-
rabbit, Cell Signaling, Manassas, VA) was applied at 1:2000 dilution. 
 
3.3.7 Statistical Analysis 
Differences between groups were determined by Student’s t test, with p < 0.05 used as a cutoff 
for significance. 
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3.4 RESULTS 
3.4.1 Indomethacin treated hearts exhibit reduced saturation of NO2-FA 
The nitroalkene saturase prostaglandin reductase-1 (PGR1) is inhibited by a variety of 
cyclooxygenase inhibitors, with indomethacin exhibiting the greatest potency (96). It was 
hypothesized that isolated perfused hearts treated with indomethacin would tend to 
metabolize NO2-FA by beta oxidation rather than reduction of the nitroalkene moiety. 
Indomethacin (or DMSO vehicle) was included in the perfusate at 200 µM, and lipids 
extracted from a flash-frozen heart after 15 min infusion and 30 min washout of 5 µM 
OANO2. LC-MS/MS of the lipid extract resolved the parent compound (18:1) and its β-
oxidation products (16:1, 14:1), as well as the saturated nitroalkanes at each chain length 
(18:0, 16:0, 14:0, and 12:0) (Figure 12a). Relative peak areas (unsaturated/saturated) in 
treated and untreated hearts were determined and a reduction in saturated metabolites at 
each chain length was noted in the indomethacin treated hearts (Figure 12b).  
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Figure 12. Impact of indomethacin on NO2-FA metabolites in heart. Isolated perfused hearts 
were infused with 5 µM OANO2 for 15 min followed by 30 min washout. Perfusate contained 200 
µM indomethacin or DMSO vehicle at 1:1000. Following flash-freeze, lipids were extracted from 
homogenized heart tissue and determined by HPLC-MS/MS. a) Chromatogram for OANO2 and 
saturation/β-oxidation products. b) Peak area ratios for unsaturated nitroalkenes to nitroalkanes 
at carbon chain lengths 18, 16 and 14. Representative data from one experiment (upper panel). 
Fold change in unsaturated/saturated ratio in indomethacin treatment versus control for 3 
independent experiments (means ± SD) (lower panel). 
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3.4.2 Indomethacin promotes availability of electrophilic nitroalkenes for thiol 
adduction 
Indomethacin- or vehicle-treated hearts were also subjected to analysis of total thiol 
adduction by NO2-FA. 100 mg of flash frozen tissue was homogenized and split into two 
fractions, one of which was treated with 20 mM N-ethylmaleimide (NEM) for 1 h. NEM 
competes for thiol binding with NO2-FA, which is found only in the free (non-thiol adducted 
state) after treatment with excess NEM. Following the NEM incubation, lipids from treated 
and untreated fractions were extracted in the presence of a 13C internal standard for 
OANO2. The normalized peak areas for each NO2-FA chain length in the untreated fraction 
were subtracted from the corresponding peak areas in the NEM-treated fraction, with the 
difference corresponding to the protein- and low molecular weight thiol-adducted NO2-FA 
pool. Nitroalkene β-oxidation products of OANO2 were determined and peak areas 
normalized to a 13C-OANO2 internal standard (added prior to lipid extraction). Indomethacin 
pretreatment augmented the levels of 16:1 and 14:1 NO2-FA in hearts (Figure 13a and 
13b), likely reflecting both the decrease in saturation of these shorter chain species and 
increased availability of 18:1 for β-oxidation. 18-, 16-, and 14-carbon NO2-FA all exhibited a 
greater degree of thiol binding in indomethacin- versus vehicle-treated hearts (Figure 13c), 
which reflects changes in glutathione (GSH) conjugate formation and protein binding. 
Finally, total fatty acid nitroalkene levels (adducted+free) were also elevated in the 
presence of indomethacin (Figure 13d). Together, these data suggest that indomethacin 
preserves the activating double bond in NO2-FA, resulting in higher levels of free and thiol-
adducted electrophilic nitroalkenes despite active β-oxidation.  
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 Figure 13. Indomethacin effects on free, thiol adducted and total nitroalkene levels. 
Following OANO2 treatment with or without indomethacin as above, lipid extracts were 
performed on frozen heart tissue in the presence and absence of 20 mM N-ethylmaleimide 
(NEM), and the increase in nitroalkene with NEM incubation was considered the thiol-adducted 
pool. a) Nitroalkene metabolite peak areas from a representative experiment. b) Fold change in 
free nitroalkene levels for indomethacin treatment versus DMSO vehicle from 3 independent 
experiments (means ± SD). c) Fold-induction of thiol-adducted nitroalkenes of 18, 16, and 14 
carbon chain lengths in the presence of indomethacin versus vehicle. Means ± SD for 3 
independent experiments. d) Fold change in total (free+adducted) nitroalkene in indomethacin 
treated hearts versus control (3 independent experiments, means ± SD). 
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3.4.3 Indomethacin treatment prevents NO2-FA metabolism and enhances 
signaling in H9C2 cells 
Given the enhanced availability of and thiol adduction by NO2-FA observed in indomethacin-
treated hearts, it was hypothesized that this PGR1 inhibitor would promote signaling by NO2-FA 
in cells. H9C2 rat cardiomyoblasts were treated with 2.5 µM OANO2, which significantly induced 
HO-1 expression at 24 h. This induction was significantly increased in the presence of 50 µM 
indomethacin (Figure 14a). In addition, metabolites were determined from methanol extraction 
of the media at 30 min intervals for 90 min and again at the time of cell harvesting (24 h). These 
data demonstrate that OANO2 is, at least initially, maintained at significantly elevated levels in 
the presence of indomethacin (Figure 14b). Further, the electrophilic metabolites of OANO2 
(16:1, 14:1) are significantly increased even at 24 h (Figure 14b). While there was a trend 
toward reduced levels of 18:0 and 16:0 with indomethacin treatment over the first 90 min, this 
did not achieve significance (Figure 14c). Overall, these analyses support the notion that 
indomethacin enhances the signaling efficacy of OANO2 by preventing its metabolism into non-
electrophilic species.  
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Figure 14. Indomethacin-induced changes in OANO2 metabolism and signaling in H9C2 
cells. H9C2 cells were grown to 80% confluency in 6 well plates and treated with 0 or 2.5 µM 
OANO2, following addition of 50 µM indomethacin (or DMSO vehicle). Media was sampled 
every 30 min for 90 min, and at 24 h, with metabolites determined by LC/MS. Cells were 
harvested and lysed at 24 h, and Western blotting for HO-1 was performed on cell extracts. a) 
Western blot for HO-1, data in triplicate (upper panel). Densitometry analysis (lower panel). 
Means ± SD. b) Peak areas for OANO2 over time from indomethacin and vehicle treated wells 
(upper panel), as well as electrophilic 16:1 (middle panel) and 14:1 (lower panel) nitroalkenes. 
c) Peak areas over time for nitroalkanes 18:0 (upper panel) and 16:0 (lower panel); *, p < 0.05 
by Student’s t test versus vehicle control. 
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3.4.4 Etomoxir reduces NO2-FA beta oxidation, promoting reduction to the 
nitroalkane 
NO2-FA are metabolized by beta oxidation in vivo, and CoA and carnitine derivatives have been 
identified in tissue and plasma, respectively, of OANO2-treated animals. How disruption of this 
signaling pathway impacts metabolism and signaling by NO2-FA has not been shown, however. 
H9C2 cells were treated with 50 µM etomoxir and metabolites measured in media as above. 
While no difference in the disappearance of OANO2 was observed compared to control, 16:1 
levels were decreased over the first 90 min and 14:1 levels depressed at 24 h with etomoxir 
treatment (Figure 15a). Conversely, 18:0 levels were elevated during the first 90 min, while 16:0 
was increased at 24 h (Figure 15b).  
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 Figure 15. Etomoxir effects on OANO2 metabolism in H9C2 cells. H9C2 cells were treated 
with 2.5 µM OANO2, with or without prior addition of 50 µM etomoxir. Media was sampled every 
30 min for 90 min and at 24 h, followed by LC/MS determination of OANO2 and metabolites. a) 
OANO2 peak area over time from wells treated with etomoxir versus control (upper panel), and 
peak areas for electrophilic nitroalkenes 16:1 (middle panel) and 14:1 (lower panel). c) Peak 
areas for nitroalkanes 18:0 (top panel) and 16:0 (lower panel). n = 3, mean ± SD; *, p < 0.05 by 
Student’s t test versus vehicle control. 
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3.4.5 Hypoxia inhibits beta oxidation and promotes saturation of NO2-FA 
Hypoxic conditions may promote the availability of reducing equivalents (e.g. NADPH) for 
PGR1-mediated saturation of nitroalkenes, and also prevent efficient beta oxidation of NO2-FA. 
We sought to determine the effect of hypoxia on NO2-FA metabolism in the isolated perfused 
heart using perfusates equilibrated with 5% CO2/95% N2 or 5% CO2 / 95% O2. Hearts were 
treated as before with 5 µM OANO2 for 15 min, with an additional 30 min washout, and flash 
frozen prior to lipid extraction. Peak area ratios of saturated to unsaturated species for 18, 16, 
and 14 carbon chains were elevated in the hypoxic hearts relative to high oxygen controls 
(Figure 16a). As expected, β-oxidation products of OANO2 were decreased under hypoxic 
conditions (Figure 16b). 
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 Figure 16. Hypoxia effects on OANO2 metabolism by the isolated heart. Isolated perfused 
hearts were perfused with KH buffer equilibrated with 95% O2 / 5% CO2 or 95% N2 / 5% CO2 for 
30 min, followed by infusion of 5 µM OANO2 for 15 min followed by 30 min washout. Hearts 
were flash-frozen, lipids extracted from homogenates and metabolites determined by LC/MS. a) 
Peak area ratios of reduced nitroalkanes to nitroalkenes at 18, 16, and 14 carbon chain lengths 
in hypoxic and normoxic hearts. b) 16- and 14-carbon nitroalkene peak areas expressed as 
fractions of OANO2 peak area. 
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3.5 DISCUSSION 
Inhibition of the electrophile-inactivating enzyme PGR1 with indomethacin increased nitroalkene 
to nitroalkane ratios in isolated hearts treated with OANO2. Electrophilic nitroalkene β-oxidation 
products of OANO2 were also evident at enhanced levels in indomethacin-treated hearts relative 
to controls.  This likely reflected the impact of PGR1 inhibition on the increased availability of 
OANO2 for mitochondrial metabolism. This was consistent with indomethacin-induced inhibition 
of metabolism of OANO2, lower levels of saturated OANO2, metabolites over the first 90 min and 
increased in 16 and 14 carbon electrophilic nitroalkenes metabolites 90 min and 24 hr after 
OANO2 addition to cells. In cardiomyocyte-based observations, the appearance of 18:0 was 
blunted less dramatically by indomethacin than the disappearance of 18:1, which may also 
suggest the involvement of another indomethacin target in NO2-FA metabolism.  
The relevance of decreased PGR1 metabolism in the indomethacin-treated isolated 
heart to NO2-FA signaling was implied by enhanced protein adduction by OANO2 and its 
electrophilic 16 and 14 carbon β-oxidation metabolites. While this analysis defines net 
electrophilic fatty acid-protein adduction reactions, it is presumed that specific signaling targets 
would also be modified to a greater extent by indomethacin. Indeed, in H9C2 cardiomyocytes, 
indomethacin enhanced the magnitude of OANO2-induced expression of the Nrf2 target gene 
HO-1. Indomethacin itself is not protective in cardiac IR, and in some studies blunts the effects 
of cardioprotective agents whose mechanisms rely on the production of vasodilatory 
prostaglandins (100). Because proposed mechanisms of OANO2-mediated cardioprotection do 
not involve prostaglandin generation, indomethacin pretreatment or co-administration may 
enable tissue preservation at lower OANO2 concentrations. Given the broad tissue expression 
of PGR1, this principle may apply in vivo to NO2-FA effects in a variety of inflammatory 
processes. Further, as PGR1 “deactivates” a multitude of electrophilic substrates, including α,β-
unsaturated ketones and nitroalkenes (95,96), the inhibition of this enzyme by indomethacin 
other clinically-prescribed COX inhibitors may prevent the metabolism of these agents, 
increasing the half-life of electrophilic compounds.  
Inhibition of β-oxidation with etomoxir significantly reduced levels of shorter chain 
nitroalkene OANO2 metabolites in H9C2 cells, while concomitantly enhancing the formation of 
non-electrophilic nitroalkanes having 18, 16, and 14 carbon chain lengths. While protein 
adduction was not assessed in this cell model, it would be anticipated that the reduction in 
electrophile levels would limit target protein thiol adduction and downstream signaling reactions. 
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In aggregate, these analyses in the presence of indomethacin and etomoxir suggest that PGR1-
mediated reduction is an important inactivation pathway than β-oxidation for NO2-FA signaling.  
Another NO2-FA clearance pathway not examined in this study is conjugation to 
glutathione (GSH), which occurs via both non-enzymatic Michael addition and enzymatic 
catalysis by glutathione-S-transferases (GSTs), followed by export through multidrug resistance 
proteins (MRPs). Whether GSTs or Michael addition are responsible for the formation of GSH-
NO2-FA adducts in vivo is unclear. While a previous study suggest that fatty acid nitroalkenes 
are poor substrates for and good inhibitors of several GST isoforms in vitro, overexpression of 
the GSTP1a isoform potently inhibited PPARγ-mediated signaling by LNO2. As GSH-LNO2 
adducts were not measured following GSTP1a overexpression, this may have been due to 
enzymatic GSH conjugation or sequestration of LNO2 by reactive thiols on GST (101). Because 
GSTs are often expressed at elevated levels in inflamed tissue, including heart following 
reperfusion, this mode of NO2-FA metabolism may be particularly relevant in diseased target 
organs (102). In addition, electrophile activation of the Nrf2/Keap1 pathway upregulates GSTs, 
so this pathway may play a greater role in NO2-FA clearance with repeated administration (103). 
GSTs are overexpressed in many cancers and contributes to chemotherapy resistance, and 
several GST inhibitors are in development for use as adjuvant cancer therapies (104). These 
compounds will aid our understanding of the contributions of GSTs to electrophile inactivation, 
and may have a role in enhancing the efficacy of electrophilic therapeutics as well. Finally, 
regardless of GST involvement in the formation of GSH-nitroalkene conjugates, MRP1 export is 
an important pathway in clearance of GSH adducts, and its expression decreases NO2-FA 
signaling (105).  
The effect of hypoxia on NO2-FA metabolism in the intact heart was also examined. 
Despite reports that the PGR1 cofactor NADPH does not accumulate in hypoxia like NADH, we 
observed an increase in nitroalkane metabolites of OANO2 under low O2 conditions. As 
anticipated, β-oxidation of OANO2 was reduced in hypoxia. Though the effects on thiol binding 
are yet to be determined; one might anticipate increased binding based on other published 
work. In one previous study a biotinylated derivative of the electrophile 15-deoxy-prostaglandin 
J2 (15d-PGJ2) displayed enhanced protein binding when incubated with thoracic aorta under 
hypoxic conditions versus normoxia (106). This was attributed to the reduction of partially 
oxidized sulfenic acid (-SOH)-containing cysteine residues under hypoxic conditions, as 
previously shown (107). Other thiol modifications have been shown to increase under hypoxic 
conditions as well, including S-nitrosation and glutathionylation (108,109). 
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The implications of this study are that PGR1-mediated reduction of NO2-FA represents a 
critical pathway for electrophile removal in myocardium, and that pharmacological inhibition of 
this pathway provides a mechanism for enhancing NO2-FA signaling. In contrast, 
pharmacological inhibition of β-oxidation appears to shift metabolism away from the generation 
of shorter chain electrophiles and toward reduced, non-electrophilic nitroalkanes. Finally, while 
hypoxia appears to enhance PGR1-mediated inactivation of NO2-FA (possibly by increasing 
NADPH levels), the increase in reduced protein thiol availability at low O2 may compensate for 
this, allowing increased protein binding and signaling.  
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4.0  DISCUSSION 
Nitric oxide (NO) is a diffusible and lipophilic mediator which facilitates physiological processes 
in nearly all tissues studied, from vasodilation in arterioles to neurotransmission in the CNS. 
Inflammatory conditions lead to the generation of secondary oxides of nitrogen from NO which 
modify macromolecules to influence cellular function. Of relevance to the current work, 
unsaturated fatty acids undergo nitration by the free radical nitrogen dioxide (.NO2) to generate 
electrophilic NO2-FA. In vivo, .NO2 is produced by the homolytic scission of the peroxynitrous 
acid (ONOOH) or nitrosoperoxycarbonate (ONOOCO2), the one-electron oxidation of nitrite 
(NO2-) by heme peroxidases, or from the decomposition of nitrous acid (HNO2) formed from 
NO2- in acidic environments (110). Once produced, NO2-FA adduct nucleophilic amino acid 
residues, modulating protein function and affecting gene expression in a pattern that is overall 
anti-inflammatory (111). 
Recent data have shown that the primary lipid target of .NO2-mediated nitration is 
conjugated linoleic acid (CLA), a group of linoleic acid isomers (18 carbons, 2 double bonds, 
most commonly cis-9,trans-11 CLA (c9,t11-CLA), and trans-10,cis-12 CLA (t10,c12-CLA)) in 
which the double bonds form a conjugated diene (112). This moiety is ~20-fold more 
susceptible to nitration than the methylene-interrupted double bond system in linoleic acid, or 
the single double bond in oleic acid (18:1) (57). The nitro-cLA (cLNO2) generated by this 
mechanism has two potential electrophilic carbons and reduced stability compared to the 
nitroalkene compounds used pharmacologically in the present studies (LNO2 and OANO2), and 
may exhibit cell signaling differences from these better-characterized species. Notably, the 
susceptibility of cLNO2 to reduction by PGR1, which the above data show is a critical mediator 
of NO2-FA metabolism, is markedly increased relative to that of LNO2 or OANO2 (95). Synthetic 
chemistry strategies for the production of cLNO2 are still in development; future work will seek to 
compare its signaling activity and therapeutic potential to other fatty acid nitroalkenes.  
CLA is produced from linoleic acid during its biohydrogenation to stearic acid (18:0) by 
bacterial enzymes in the gut of ruminants, and consumed in beef and dairy products (113). Like 
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n-3 fatty acids, CLA is noted for its biological activities and commercially available as a dietary 
supplement. Among the beneficial properties attributed to CLA in disease models are anti-
atherosclerotic effects, cancer chemoprevention, and attenuation of obesity (113-115). 
Intriguingly, these same effects are reported or under investigation for NO2-FA and/or other 
electrophiles (53,91,93), raising the possibility that some of the observed anti-inflammatory 
signaling actions of CLA are due to its “activation” to an electrophilic nitroalkene. To probe this 
hypothesis, LC/MS analysis of tissues from CLA-treated animals can be used to demonstrate 
formation of cLNO2 and its metabolites, coupled with proteomic analysis to determine adduction 
of critical proteins by cLNO2, or with immunoblotting to demonstrate upregulation of Nrf2 target 
genes such as HO-1. In a recent study validating gastric nitration of CLA by nitrite, the latter 
approach was used to show that HO-1 upregulation occurs alongside cLNO2 generation in the 
GI tract when nitrite and CLA are administered together, but not with either treatment alone (57). 
Another possibility would be testing the effect of nitric oxide synthase (NOS) knockdown or 
inhibition on the protective effects of CLA.  
The nitration of CLA to cLNO2 may occur in any compartment where CLA and .NO2 
coexist. These include the stomach, where acidified dietary nitrite may facilitate nitration of CLA 
in the lumen, inflammatory cells such as activated macrophages where iNOS induction provides 
abundant oxides of nitrogen, or in mitochondria, where high lipid content, low pH and reactive 
species generation may all coincide, particularly under inflammatory conditions (e.g. ischemia). 
Indeed, the addition of nitrite alone to isolated rat heart mitochondria under mildly acidic 
conditions promotes the nitration of endogenous CLA (57). Mitochondria are also a noted 
source of endogenous fatty acid nitroalkene production in ischemic preconditioning (31), and it 
is now known that the endogenous LNO2 reported in these studies was most likely the cLNO2 
isomer. The observation that conjugated double bonds are readily nitrated in vivo has 
interesting implications. For instance, nitration of the amino acid tyrosine by .NO2, often used as 
a biomarker of oxidative stress, is a much less thermodynamically favorable process than CLA 
nitration, as addition of tyrosine in 500 molar excess fails to impair the latter reaction (57). This 
suggests that cLNO2 or its protein adducts may be a more sensitive biomarker of oxidative 
stress and nitrating reactions than nitrotyrosine, and with the detection of cLNO2 and its 
metabolites in human  urine this may prove clinically relevant (57). In addition, other compounds 
containing conjugated double bond systems (including polyene pigments such as carotenoids) 
may be subject to biological nitration (107). Research is underway to identify additional nitro-
containing electrophiles in post-ischemic tissue. 
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The mitochondrial origin of endogenous fatty acid nitroalkenes and the role of 
mitochondria in adaptive redox signal transduction motivated the study of their mitochondrial 
effects. While all respiratory complexes are inhibited by various thiol-reactive compounds, 
complex II was most sensitive to inhibition by NO2-FA. Complex II consists of four polypeptide 
subunits and five prosthetic groups (flavin adenine dinucleotide, three iron-sulfur centers, heme 
b) and occupies a unique niche as a direct link between electron transport and the TCA cycle 
(as succinate dehydrogenase), catalyzing the reduction of ubiquinone coupled to the oxidation 
of succinate to fumarate (108). While other dehydrogenases can couple ubiquinone reduction to 
the oxidation of organic compounds, these enzymes are structurally less intricate, leading to 
speculation that complex II has additional functions (109). For example, the small subunit of 
cytochrome b (subunit D) in complex II has been proposed to function as an O2 sensor, as 
mutations in this subunit have been linked to hereditary paragangliomas, benign tumors of the 
carotid body phenotypically similar to the sporadic form caused by chronic hypoxia (92). In 
addition, complex II inhibition is linked to the opening of a mitochondrial KATP channel, though 
the molecular identity of this channel is unknown and the relationship of complex II proteins to 
its activity unclear (112). Further, interference with complex II activity influences superoxide 
production at complexes I and III (80). Combined with the role of complex II in cellular 
respiration, one or more of these functions could provide a mechanistic link between inhibition of 
complex II and cardioprotection in IR. Because reactive species generation and mito-KATP 
channel activity were not measured here, future efforts may be directed toward understanding 
the effects of fatty acid nitroalkenes on these parameters.  
Redox modifications of complex II are myriad and often discussed in the context of 
irreversible damage to electron transport and loss of mitochondrial function. Rat heart 
mitochondria show reduced complex II activity and 4-hydroxynonenal (HNE) modification of the 
70-kDa Fp subunit (by Western blot) following induction of diabetes by an intraperitoneal 
injection of streptozotocin (112).  During reperfusion injury, complex II undergoes tyrosine 
nitration concomitant with a loss of electron transport activity (113). In isolated mitochondria, 
treatment with Angeli’s salt (HNO) leads to oxidation of a thiol near the active site and loss of 
activity (71). There are also data suggesting a more positive role of post-translational thiol 
modifications in complex II: a loss of glutathionylation from the 70-kDa subunit accompanies 
reperfusion injury, and in vitro data show that a loss of GSH adducts correlate with decreased 
electron transfer efficiency and increased O2.- formation (90). Additional work is required to 
reconcile the presence of oxidative “damage” to complex II in injured or inflamed tissue with the 
apparent benefits of its inhibition in IR, though the reversible binding of many cardioprotective 
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complex II inhibitors (including NO2-FA), in contrast with the relative irreversibility of thiol 
oxidation to sulfinic/sulfonic acid or HNE adduction provides a partial explanation (114,115). 
Timing of compound administration may also play an important role in determining the effect of 
complex II inhibition. For example, HNO has protective effects when used as a pretreatment in 
IR, but exacerbates injury when added during reperfusion (116,117). 
In aggregate the data presented herein suggest a cardioprotective mechanism for NO2-
FA involving a shift from respiratory to glycolytic metabolism. This approach to protecting 
ischemic heart tissue has its historical origins in the 1960s, when glucose, insulin, and 
potassium (GIK) treatment of acute MI was first conceptualized (51). Insulin was used to 
prevent myocardial uptake of free fatty acids, which are systemically released during MI 
secondary to elevated stress-induced catecholamine levels, with glucose provided as an 
alternative energy source (potassium was used primarily to aid in recovery of sinus rhythm) 
(118,119). While GIK therapy never became standard practice and its efficacy is still debated, 
the reasoning underlying its use (i.e. that glucose oxidation is a more efficient use of O2 and 
should be promoted under hypoxic conditions) remains appealing. In stable severe angina 
pectoris, where stress-induced myocardial O2 demand outstrips supply causing chest pain, β-
oxidation inhibitors such as perhexiline (a highly efficacious but somewhat toxic inhibitor which 
acts on carnitine palmitoyl transferase 1 (CPT1)), trimetazidine, and ranolazine (both long-chain 
3-ketoacyl-CoA thiolase inhibitors with moderate anti-angina activity) have been successfully 
employed in the clinic, though none are first-line therapies (120). Etomoxir, used in the present 
work to inhibit β-oxidation of fatty acid nitroalkenes at the level of CPT1, was used as a 
congestive heart failure therapy in the ERGO (etomoxir for the recovery of glucose oxidation) 
trial. This study was halted due to elevations of liver transaminases in plasma, though trends 
toward improved exercise time were observed in the treatment group (121). Together these 
examples confirm that shifting metabolism away from fatty acid oxidation and toward glycolysis 
is clinically effective in ischemic heart disease, though there are concerns about systemic 
toxicity with certain molecular targets or chronic use. Thus, developing metabolic agents with 
improved safety profiles is a priority, and NO2-FA may meet this criterion. A more direct 
approach to this issue can be seen in a recent study in which a cell-based screen of FDA-
approved medications identified the anti-nausea medication meclizine (a histamine receptor 
antagonist) as a mediator of the metabolic transition from respiration to glycolysis, and followed 
this with a demonstration of its protective ability in cardiac and cerebral IR (62). Clearly a 
medication with a known safety profile would be an ideal candidate for clinical use.  
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The realization that superoxide and its byproducts play a deleterious role in inflammatory 
disease has led to decades of research on free radical and oxidant scavengers, both naturally 
occurring (ascorbate, tocopherols, N-acetylcysteine, catalase and superoxide dismutase (SOD)) 
and synthetic (manganese porphyrin SOD mimetics). While in certain contexts these 
approaches have proven safe and effective (N-acetylcysteine in acetaminophen-induced liver 
injury, for instance (122)), overall drugs directly targeting free radicals have failed to live up to 
their promise. A large, randomized controlled trial of d-α-tocopherol (vitamin E) supplementation 
in a population at high cardiovascular risk (the HOPE study) showed no benefit and modest 
trends toward adverse cardiovascular events in the supplement group (123). Clinical trials with 
ascorbate (vitamin C) have also failed to show positive impacts on cardiovascular morbidity and 
mortality, though slight decreases in blood pressure are frequently observed (124,125). While 
several studies have shown the benefits of native SOD and catalase administration in IR 
(126,127), the short half-life, antigenicity and cost of protein-based therapies makes them 
impractical options. SOD mimetics, such as the manganese metalloporphyrins, have been 
developed to improve on these parameters, with success in experimental models (128). These 
compounds vary in their selectivity for superoxide versus other reactive species, catalytic 
efficiency and cell permeability, and clinical trials are ongoing for multiple agents (129). More 
recently, agents have been developed with the goal of scavenging ROS in specific 
compartments. The addition of a triphenylphosphonium moiety is a popular method of targeting 
redox active compounds to mitochondria, as its delocalized positive charge and lipophilicity 
promote matrix accumulation. These mitochondrially-targeted antioxidants are also effective in 
cardiovascular disease models (130). Regardless of the efficacy of these approaches in 
inflammation, there is emerging evidence that suppression of “adaptive” free radical generation 
is harmful, which may be problematic when indiscriminate radical scavengers are used. For 
example, the insulin sensitivity-promoting effects of exercise are suppressed by 
supplementation of vitamins C and E (131).  
The therapeutic benefits of oxidant-derived nitro-fatty acids (and perhaps by extension 
other electrophiles produced under inflammatory conditions) suggest that in vivo generation and 
signaling of these compounds represents one such adaptive response to oxidative stress. In 
addition to insulin sensitization as mentioned above, current evidence indicates that free 
radicals are involved in ischemic preconditioning (116) and adaptive vascular responses to 
stress (117). If mild oxidant stress can be viewed as beneficial, this provides a rationale for the 
pharmacological use of oxidant-generated signaling compounds to enhance native defense 
mechanisms. Endogenous free radical and electrophile generation are typically under tight 
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control, and various genomic pathways have evolved to sense reactive species and upregulate 
enzymes which promote their detoxification. Administration of reactive species at sub-toxic 
doses represents one pharmacological approach for increasing expression of antioxidant and 
electrophile-detoxifying genes and preventing tissue injury in inflammation. The Nrf2/Keap1 and 
heat shock response pathways are two well-characterized example of this. Keap1 is a cysteine-
rich E3 ubiquitin ligase that binds Nrf2 in the cytosol and tags it for degradation. Oxidation or 
electrophilic Michael addition of Keap1 thiols frees Nrf2 which then migrates to the nucleus, 
binding to gene promoters containing an antioxidant response element (ARE) and amplifying 
their expression. Proteins such as NAD(P)H:quinone oxidoreductase-1 NQO1, enzymes of the 
GSH synthetic pathway, glutathione-S-transferase (GST), and heme oxygenase-1 (HO-1) are 
among the Nrf2 target genes which protect the cell against oxidative damage (25). Analogously, 
heat shock factor-1 (HSF1), basally inactive in the cytosol and bound to heat shock proteins 
(HSPs) 40, 70 and 90, is released for nuclear translocation by a variety of stresses that induce 
protein damage and misfolding including including high temperature, oxidative stress, and 
electrophile adduction, and following hyperphosphorylation in the nucleus binds to gene 
promoters containing heat shock elements (HSE). HSP chaperone expression is increased 
through this pathway, promoting proper protein conformation and preventing aggregation (27). 
Electrophilic mediators currently under study as potential pharmacological agents, including 
triterpenoids, sulforaphane, and fatty acid nitroalkenes, activate the antioxidant and heat shock 
response pathways as part of their mechanism of action. Further, in the present work it is 
suggested that mitochondrial responses to electrophiles may constitute an acute stress-
response pathway, altering metabolism to mediate protection in IR. Whether this approach is 
clinically viable, and in which pathologies it will be most effective, is yet to be determined. 
Another important pharmacological issue for NO2-FA addressed here was the 
metabolism of the active parent compound. Fatty acid nitroalkenes are subject to the same 
metabolic pathways as other fatty acids: they undergo β-oxidation in mitochondria, in the 
process forming shorter chain nitroalkenes and CoA and carnitine derivatives, and are likely 
esterified to phospholipids and triglycerides (detection of nitroalkene-containing complex lipids is 
an ongoing project in the laboratory) (86). By virtue of their electrophilic functionality, they are 
also metabolized by protein thiol adduction, the nitroalkene reductase activity of prostaglandin 
reductase 1 (PGR1) and adduction by GSH followed by export through MRP1. While decreases 
in MRP1 and PGR1 activity enhance NO2-FA signaling, it is less clear whether blocking fatty 
acid metabolism yields similar results. Likely this is because short chain nitroalkenes, CoA and 
carnitine derivatives, and esterified NO2-FA retain electrophilicity. Further, it is reasonable to 
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speculate that fatty acid trafficking alters NO2-FA signaling relative to that of other electrophiles: 
under conditions where cells rely on β-oxidation to meet their energetic needs, local 
concentrations of fatty acid nitroalkenes in mitochondria would be expected to increase, 
enhancing adduction of mitochondrial versus cytosolic protein targets. As myocardial 
reperfusion is one such situation, NO2-FA may represent mitochondrially targeted metabolic 
modulators for IR.  
In conclusion, this work shows that fatty acid nitroalkenes mediate acute 
cardioprotection from IR in the isolated heart, and inhibit respiration in cultured cardiomyoblasts, 
likely via reversible adduction of complex II, promoting glycolytic flux. In addition, PGR1-
mediated saturation of NO2-FA in heart tissue and cardiomyoblasts was identified as a critical 
means of inactivation for this electrophile relative to β-oxidation, and pharmacological inhibition 
of the former pathway emerged as a potential means of enhancing nitroalkene signaling in 
myocardium. Preliminary results from studies conducted at low pO2 suggest that NO2-FA 
metabolism and signaling may also be altered in the hypoxic myocardium. Together these 
studies suggest a novel mechanism of action for an emerging class of cardioprotective 
mediators, and reveal methods of analyzing and optimizing their metabolism and signaling by 
the heart. 
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5.0  APPENDIX A: SUPPLEMENTAL INFORMATION 
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Figure 17. 3-NP does not inhibit OANO2 binding to the Fp subunit of complex II. 100 μg of 
mitochondrial lysate was incubated with 5 μM OANO2 following pre-incubation with varying 
concentrations of 3-nitropropionate (0, 20 or 50 μM) followed by SDS-PAGE and protein 
labeling by Coomassie stain. The band corresponding to the 70 kDa subunit of complex II was 
removed, dried with ACN and rehydrated in the presence of 500 mM BME. Peak areas for BME-
OANO2 adducts are shown for 0, 20, and 50 μM OANO2. 
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Figure 18. Ascorbate/TMPD rescues respiratory inhibition by OANO2. Freshly isolated rat 
heart mitochondria (0.5 mg, all RCR > 4) were incubated in respiration buffer (pH 7.2) for 5 min 
with OA or OANO2 (5 μM) prior to substrate addition. Representative O2 concentration traces 
following addition of the complex II-linked substrate succinate (10 mM) are show. After 500 s (to 
establish inhibition by OANO2), 20 mM ascorbate and 20 µM TMPD were added to both 
chambers. 
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ABBREVIATIONS 
NO2-FA, nitro-fatty acids; OANO2, nitro-oleic acid; OA, oleic acid; TMPD, 
tetramethylphenylenediamine; FCCP, BME, β-mercaptoethanol. HNE, hydroxynonenal. OCR, 
oxygen consumption rate. ECAR, extracellular acidification rate. RCR, respiratory control ratio. 
3-NP, 3-nitropropionic acid, XF, extracellular flux. UCP, uncoupling protein; PUFA, 
polyunsaturated fatty acids; ROS, reactive oxygen species; RNS, reactive nitrogen species; 
FAO, fatty acid oxidation; PTP, permeability transition pore; IMM, inner mitochondrial 
membrane; OMM, outer mitochondrial membrane; SERCA, sarco/endoplasmic reticulum 
calcium ATPase; T2DM, type 2 diabetes mellitus; 4-HNE, 4-hydroxynonenal; 4-ONE, 4-
oxononenal; 15-dPGJ2, 15-deoxy-prostaglandin J2; COX, cyclooxygenase; LOX, lipoxygenase; 
oxo-ETE, oxo-eicosatetraenoic acid; ONOO-, peroxynitrite; .NO2, nitrogen dioxide; NO2-, nitrite; 
L., lipid alkoxyl radical; LOO., lipid peroxyl radical; TZD, thiazoladinedione; NF-κB, nuclear factor 
κB; PPARγ, peroxisome proliferator-activated receptor g; Nrf2, nuclear erythroid 2-related factor 
2; Keap1, kelch ECH associating protein; GSH, glutathione; TNF-α, tumor necrosis factor α; 
NADH, nicotinamide adenine dinucleotide (reduced); NAD+, nicotinamide adenine dinucleotide 
(oxidized). 
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